{ "instance": { "tmb-20230630x10q.htm": { "axisCustom": 0, "axisStandard": 20, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 618, "http://xbrl.sec.gov/dei/2023": 31 }, "contextCount": 172, "dts": { "calculationLink": { "local": [ "tmb-20230630_cal.xml" ] }, "definitionLink": { "local": [ "tmb-20230630_def.xml" ] }, "inline": { "local": [ "tmb-20230630x10q.htm" ] }, "labelLink": { "local": [ "tmb-20230630_lab.xml" ] }, "presentationLink": { "local": [ "tmb-20230630_pre.xml" ] }, "schema": { "local": [ "tmb-20230630.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "elementCount": 482, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2023": 10, "http://www.petrospharma.com/20230630": 4, "http://xbrl.sec.gov/dei/2023": 5, "total": 19 }, "keyCustom": 76, "keyStandard": 219, "memberCustom": 46, "memberStandard": 21, "nsprefix": "ptpi", "nsuri": "http://www.petrospharma.com/20230630", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "tmb-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_bGPcSN_Lv0anGo0Q8w56yw", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00090 - Document - Document and Entity Information", "menuCat": "Cover", "order": "1", "role": "http://www.petrospharma.com/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "tmb-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_bGPcSN_Lv0anGo0Q8w56yw", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "tmb-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_bGPcSN_Lv0anGo0Q8w56yw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10401 - Disclosure - Inventories", "menuCat": "Notes", "order": "10", "role": "http://www.petrospharma.com/role/DisclosureInventories", "shortName": "Inventories", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "tmb-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_bGPcSN_Lv0anGo0Q8w56yw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "tmb-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_bGPcSN_Lv0anGo0Q8w56yw", "decimals": null, "first": true, "lang": "en-US", "name": "ptpi:SummaryOfPrepaidExpensesAndOtherCurrentAssetsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10501 - Disclosure - Prepaid Expenses and Other Current Assets", "menuCat": "Notes", "order": "11", "role": "http://www.petrospharma.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets", "shortName": "Prepaid Expenses and Other Current Assets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "tmb-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_bGPcSN_Lv0anGo0Q8w56yw", "decimals": null, "first": true, "lang": "en-US", "name": "ptpi:SummaryOfPrepaidExpensesAndOtherCurrentAssetsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "tmb-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_bGPcSN_Lv0anGo0Q8w56yw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10601 - Disclosure - Intangible Assets", "menuCat": "Notes", "order": "12", "role": "http://www.petrospharma.com/role/DisclosureIntangibleAssets", "shortName": "Intangible Assets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "tmb-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_bGPcSN_Lv0anGo0Q8w56yw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "tmb-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_bGPcSN_Lv0anGo0Q8w56yw", "decimals": null, "first": true, "lang": "en-US", "name": "ptpi:AccruedLiabilitiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10701 - Disclosure - Accrued Expenses", "menuCat": "Notes", "order": "13", "role": "http://www.petrospharma.com/role/DisclosureAccruedExpenses", "shortName": "Accrued Expenses", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "tmb-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_bGPcSN_Lv0anGo0Q8w56yw", "decimals": null, "first": true, "lang": "en-US", "name": "ptpi:AccruedLiabilitiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "tmb-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_bGPcSN_Lv0anGo0Q8w56yw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10801 - Disclosure - Debt", "menuCat": "Notes", "order": "14", "role": "http://www.petrospharma.com/role/DisclosureDebt", "shortName": "Debt", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "tmb-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_bGPcSN_Lv0anGo0Q8w56yw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "tmb-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_bGPcSN_Lv0anGo0Q8w56yw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10901 - Disclosure - Operating Leases", "menuCat": "Notes", "order": "15", "role": "http://www.petrospharma.com/role/DisclosureOperatingLeases", "shortName": "Operating Leases", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "tmb-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_bGPcSN_Lv0anGo0Q8w56yw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "tmb-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_bGPcSN_Lv0anGo0Q8w56yw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11001 - Disclosure - Stock Options and Restricted Stock Units (\"RSU's\")", "menuCat": "Notes", "order": "16", "role": "http://www.petrospharma.com/role/DisclosureStockOptionsAndRestrictedStockUnitsrsuS", "shortName": "Stock Options and Restricted Stock Units (\"RSU's\")", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "tmb-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_bGPcSN_Lv0anGo0Q8w56yw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "tmb-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_bGPcSN_Lv0anGo0Q8w56yw", "decimals": null, "first": true, "lang": "en-US", "name": "ptpi:WarrantsAndRightsNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11101 - Disclosure - Common Stock Warrants", "menuCat": "Notes", "order": "17", "role": "http://www.petrospharma.com/role/DisclosureCommonStockWarrants", "shortName": "Common Stock Warrants", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "tmb-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_bGPcSN_Lv0anGo0Q8w56yw", "decimals": null, "first": true, "lang": "en-US", "name": "ptpi:WarrantsAndRightsNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "tmb-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_bGPcSN_Lv0anGo0Q8w56yw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11201 - Disclosure - Basic and Diluted Net Income (Loss) per Common Share", "menuCat": "Notes", "order": "18", "role": "http://www.petrospharma.com/role/DisclosureBasicAndDilutedNetIncomeLossPerCommonShare", "shortName": "Basic and Diluted Net Income (Loss) per Common Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "tmb-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_bGPcSN_Lv0anGo0Q8w56yw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "tmb-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_bGPcSN_Lv0anGo0Q8w56yw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11301 - Disclosure - Marketing, Licensing and Distribution Agreements", "menuCat": "Notes", "order": "19", "role": "http://www.petrospharma.com/role/DisclosureMarketingLicensingAndDistributionAgreements", "shortName": "Marketing, Licensing and Distribution Agreements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "tmb-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_bGPcSN_Lv0anGo0Q8w56yw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "tmb-20230630x10q.htm", "contextRef": "As_Of_6_30_2023_k7C6SKQheEy_MxotDp9Q1A", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Cash", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_vhmnjuGA6062sbON5KQrYQ", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS", "menuCat": "Statements", "order": "2", "role": "http://www.petrospharma.com/role/StatementCondensedConsolidatedBalanceSheets", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "tmb-20230630x10q.htm", "contextRef": "As_Of_6_30_2023_k7C6SKQheEy_MxotDp9Q1A", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Cash", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_vhmnjuGA6062sbON5KQrYQ", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "tmb-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_bGPcSN_Lv0anGo0Q8w56yw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11401 - Disclosure - Commitments and Contingencies", "menuCat": "Notes", "order": "20", "role": "http://www.petrospharma.com/role/DisclosureCommitmentsAndContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "tmb-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_bGPcSN_Lv0anGo0Q8w56yw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "tmb-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_bGPcSN_Lv0anGo0Q8w56yw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11501 - Disclosure - Segment Information", "menuCat": "Notes", "order": "21", "role": "http://www.petrospharma.com/role/DisclosureSegmentInformation", "shortName": "Segment Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "tmb-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_bGPcSN_Lv0anGo0Q8w56yw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "tmb-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_bGPcSN_Lv0anGo0Q8w56yw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11601 - Disclosure - Subsequent Events", "menuCat": "Notes", "order": "22", "role": "http://www.petrospharma.com/role/DisclosureSubsequentEvents", "shortName": "Subsequent Events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "tmb-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_bGPcSN_Lv0anGo0Q8w56yw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "baseRef": "tmb-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_bGPcSN_Lv0anGo0Q8w56yw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:UseOfEstimates", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "20202 - Disclosure - Summary of Significant Accounting Policies (Policies)", "menuCat": "Policies", "order": "23", "role": "http://www.petrospharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies", "shortName": "Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "baseRef": "tmb-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_bGPcSN_Lv0anGo0Q8w56yw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:UseOfEstimates", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "us-gaap:LoansNotesTradeAndOtherReceivablesExcludingAllowanceForCreditLossesTextBlock", "div", "div", "body", "html" ], "baseRef": "tmb-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_bGPcSN_Lv0anGo0Q8w56yw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30303 - Disclosure - Accounts Receivable, net (Tables)", "menuCat": "Tables", "order": "24", "role": "http://www.petrospharma.com/role/DisclosureAccountsReceivableNetTables", "shortName": "Accounts Receivable, net (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:LoansNotesTradeAndOtherReceivablesExcludingAllowanceForCreditLossesTextBlock", "div", "div", "body", "html" ], "baseRef": "tmb-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_bGPcSN_Lv0anGo0Q8w56yw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "us-gaap:InventoryDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "tmb-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_bGPcSN_Lv0anGo0Q8w56yw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30403 - Disclosure - Inventories (Tables)", "menuCat": "Tables", "order": "25", "role": "http://www.petrospharma.com/role/DisclosureInventoriesTables", "shortName": "Inventories (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:InventoryDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "tmb-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_bGPcSN_Lv0anGo0Q8w56yw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "ptpi:SummaryOfPrepaidExpensesAndOtherCurrentAssetsTextBlock", "div", "div", "body", "html" ], "baseRef": "tmb-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_bGPcSN_Lv0anGo0Q8w56yw", "decimals": null, "first": true, "lang": "en-US", "name": "ptpi:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30503 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)", "menuCat": "Tables", "order": "26", "role": "http://www.petrospharma.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables", "shortName": "Prepaid Expenses and Other Current Assets (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ptpi:SummaryOfPrepaidExpensesAndOtherCurrentAssetsTextBlock", "div", "div", "body", "html" ], "baseRef": "tmb-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_bGPcSN_Lv0anGo0Q8w56yw", "decimals": null, "first": true, "lang": "en-US", "name": "ptpi:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "tmb-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_bGPcSN_Lv0anGo0Q8w56yw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30603 - Disclosure - Intangible Assets (Tables)", "menuCat": "Tables", "order": "27", "role": "http://www.petrospharma.com/role/DisclosureIntangibleAssetsTables", "shortName": "Intangible Assets (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "tmb-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_bGPcSN_Lv0anGo0Q8w56yw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "ptpi:AccruedLiabilitiesTextBlock", "div", "div", "body", "html" ], "baseRef": "tmb-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_bGPcSN_Lv0anGo0Q8w56yw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30703 - Disclosure - Accrued Expenses (Tables)", "menuCat": "Tables", "order": "28", "role": "http://www.petrospharma.com/role/DisclosureAccruedExpensesTables", "shortName": "Accrued Expenses (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ptpi:AccruedLiabilitiesTextBlock", "div", "div", "body", "html" ], "baseRef": "tmb-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_bGPcSN_Lv0anGo0Q8w56yw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "tmb-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_bGPcSN_Lv0anGo0Q8w56yw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30803 - Disclosure - Debt (Tables)", "menuCat": "Tables", "order": "29", "role": "http://www.petrospharma.com/role/DisclosureDebtTables", "shortName": "Debt (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "tmb-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_bGPcSN_Lv0anGo0Q8w56yw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "tmb-20230630x10q.htm", "contextRef": "As_Of_6_30_2023_k7C6SKQheEy_MxotDp9Q1A", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unitRef": "Unit_Divide_USD_shares_4ILe2HwoJkSuKGzbAHXCkA", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00105 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "menuCat": "Statements", "order": "3", "role": "http://www.petrospharma.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "tmb-20230630x10q.htm", "contextRef": "As_Of_6_30_2023_k7C6SKQheEy_MxotDp9Q1A", "decimals": "INF", "lang": null, "name": "us-gaap:CommonStockSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_h85vs13OzkeGJCK-nyVGNg", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "body", "html" ], "baseRef": "tmb-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_bGPcSN_Lv0anGo0Q8w56yw", "decimals": null, "first": true, "lang": "en-US", "name": "ptpi:LesseeOperatingLeaseSupplementalBalanceSheetInformationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30903 - Disclosure - Operating Leases (Tables)", "menuCat": "Tables", "order": "30", "role": "http://www.petrospharma.com/role/DisclosureOperatingLeasesTables", "shortName": "Operating Leases (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "body", "html" ], "baseRef": "tmb-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_bGPcSN_Lv0anGo0Q8w56yw", "decimals": null, "first": true, "lang": "en-US", "name": "ptpi:LesseeOperatingLeaseSupplementalBalanceSheetInformationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_bGPcSN_Lv0anGo0Q8w56yw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "31003 - Disclosure - Stock Options and Restricted Stock Units (\"RSU's\") (Tables)", "menuCat": "Tables", "order": "31", "role": "http://www.petrospharma.com/role/DisclosureStockOptionsAndRestrictedStockUnitsrsuSTables", "shortName": "Stock Options and Restricted Stock Units (\"RSU's\") (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_bGPcSN_Lv0anGo0Q8w56yw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "ptpi:WarrantsAndRightsNoteDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "tmb-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_bGPcSN_Lv0anGo0Q8w56yw", "decimals": null, "first": true, "lang": "en-US", "name": "ptpi:ScheduleOfWarrantsAndRightsByExpirationDateTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "31103 - Disclosure - Common Stock Warrants (Tables)", "menuCat": "Tables", "order": "32", "role": "http://www.petrospharma.com/role/DisclosureCommonStockWarrantsTables", "shortName": "Common Stock Warrants (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ptpi:WarrantsAndRightsNoteDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "tmb-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_bGPcSN_Lv0anGo0Q8w56yw", "decimals": null, "first": true, "lang": "en-US", "name": "ptpi:ScheduleOfWarrantsAndRightsByExpirationDateTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "baseRef": "tmb-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_bGPcSN_Lv0anGo0Q8w56yw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "31203 - Disclosure - Basic and Diluted Net Income (Loss) per Common Share (Tables)", "menuCat": "Tables", "order": "33", "role": "http://www.petrospharma.com/role/DisclosureBasicAndDilutedNetIncomeLossPerCommonShareTables", "shortName": "Basic and Diluted Net Income (Loss) per Common Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "baseRef": "tmb-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_bGPcSN_Lv0anGo0Q8w56yw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_bGPcSN_Lv0anGo0Q8w56yw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "31503 - Disclosure - Segment Information (Tables)", "menuCat": "Tables", "order": "34", "role": "http://www.petrospharma.com/role/DisclosureSegmentInformationTables", "shortName": "Segment Information (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_bGPcSN_Lv0anGo0Q8w56yw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "tmb-20230630x10q.htm", "contextRef": "As_Of_6_30_2023_k7C6SKQheEy_MxotDp9Q1A", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_vhmnjuGA6062sbON5KQrYQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40101 - Disclosure - Nature of Operations, Basis of Presentation, Liquidity and Going Concern - Additional information (Details)", "menuCat": "Details", "order": "35", "role": "http://www.petrospharma.com/role/DisclosureNatureOfOperationsBasisOfPresentationLiquidityAndGoingConcernAdditionalInformationDetails", "shortName": "Nature of Operations, Basis of Presentation, Liquidity and Going Concern - Additional information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "tmb-20230630x10q.htm", "contextRef": "As_Of_6_30_2023_k7C6SKQheEy_MxotDp9Q1A", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_vhmnjuGA6062sbON5KQrYQ", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "p", "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20230630x10q.htm", "contextRef": "As_Of_6_30_2023_k7C6SKQheEy_MxotDp9Q1A", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ContractWithCustomerRefundLiabilityCurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_vhmnjuGA6062sbON5KQrYQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40201 - Disclosure - Summary of Significant Accounting Policies (Details)", "menuCat": "Details", "order": "36", "role": "http://www.petrospharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails", "shortName": "Summary of Significant Accounting Policies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20230630x10q.htm", "contextRef": "As_Of_6_30_2023_k7C6SKQheEy_MxotDp9Q1A", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ContractWithCustomerRefundLiabilityCurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_vhmnjuGA6062sbON5KQrYQ", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "us-gaap:LoansNotesTradeAndOtherReceivablesExcludingAllowanceForCreditLossesTextBlock", "div", "div", "body", "html" ], "baseRef": "tmb-20230630x10q.htm", "contextRef": "As_Of_6_30_2023_k7C6SKQheEy_MxotDp9Q1A", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AccountsReceivableGross", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_vhmnjuGA6062sbON5KQrYQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40301 - Disclosure - Accounts Receivable, net (Details)", "menuCat": "Details", "order": "37", "role": "http://www.petrospharma.com/role/DisclosureAccountsReceivableNetDetails", "shortName": "Accounts Receivable, net (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "us-gaap:LoansNotesTradeAndOtherReceivablesExcludingAllowanceForCreditLossesTextBlock", "div", "div", "body", "html" ], "baseRef": "tmb-20230630x10q.htm", "contextRef": "As_Of_6_30_2023_k7C6SKQheEy_MxotDp9Q1A", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AccountsReceivableGross", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_vhmnjuGA6062sbON5KQrYQ", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "p", "us-gaap:LoansNotesTradeAndOtherReceivablesExcludingAllowanceForCreditLossesTextBlock", "div", "div", "body", "html" ], "baseRef": "tmb-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_4AufylxJBkqH6ExzJn1_aQ", "decimals": "INF", "first": true, "lang": null, "name": "ptpi:NumberOfCustomers", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_customer_patcZLz1HkmU0hWHbBcpfA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40302 - Disclosure - Accounts Receivable, net - Additional information (Details)", "menuCat": "Details", "order": "38", "role": "http://www.petrospharma.com/role/DisclosureAccountsReceivableNetAdditionalInformationDetails", "shortName": "Accounts Receivable, net - Additional information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:LoansNotesTradeAndOtherReceivablesExcludingAllowanceForCreditLossesTextBlock", "div", "div", "body", "html" ], "baseRef": "tmb-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_4AufylxJBkqH6ExzJn1_aQ", "decimals": "INF", "first": true, "lang": null, "name": "ptpi:NumberOfCustomers", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_customer_patcZLz1HkmU0hWHbBcpfA", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "tmb-20230630x10q.htm", "contextRef": "As_Of_6_30_2023_k7C6SKQheEy_MxotDp9Q1A", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_vhmnjuGA6062sbON5KQrYQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40401 - Disclosure - Inventories (Details)", "menuCat": "Details", "order": "39", "role": "http://www.petrospharma.com/role/DisclosureInventoriesDetails", "shortName": "Inventories (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "tmb-20230630x10q.htm", "contextRef": "As_Of_6_30_2023_k7C6SKQheEy_MxotDp9Q1A", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_vhmnjuGA6062sbON5KQrYQ", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "tmb-20230630x10q.htm", "contextRef": "Duration_4_1_2023_To_6_30_2023_QgrawYbZDUmYHoreYKbCoA", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "Unit_Standard_USD_vhmnjuGA6062sbON5KQrYQ", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS", "menuCat": "Statements", "order": "4", "role": "http://www.petrospharma.com/role/StatementCondensedConsolidatedStatementsOfOperations", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "tmb-20230630x10q.htm", "contextRef": "Duration_4_1_2023_To_6_30_2023_QgrawYbZDUmYHoreYKbCoA", "decimals": "0", "lang": null, "name": "us-gaap:GrossProfit", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_vhmnjuGA6062sbON5KQrYQ", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "p", "us-gaap:InventoryDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "tmb-20230630x10q.htm", "contextRef": "As_Of_6_30_2023_k7C6SKQheEy_MxotDp9Q1A", "decimals": "0", "first": true, "lang": null, "name": "ptpi:InventoryFinishedGoodsValuationReserves", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_vhmnjuGA6062sbON5KQrYQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40402 - Disclosure - Inventories - Additional Information (Details)", "menuCat": "Details", "order": "40", "role": "http://www.petrospharma.com/role/DisclosureInventoriesAdditionalInformationDetails", "shortName": "Inventories - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:InventoryDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "tmb-20230630x10q.htm", "contextRef": "As_Of_6_30_2023_k7C6SKQheEy_MxotDp9Q1A", "decimals": "0", "first": true, "lang": null, "name": "ptpi:InventoryFinishedGoodsValuationReserves", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_vhmnjuGA6062sbON5KQrYQ", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "ptpi:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock", "ptpi:SummaryOfPrepaidExpensesAndOtherCurrentAssetsTextBlock", "div", "div", "body", "html" ], "baseRef": "tmb-20230630x10q.htm", "contextRef": "As_Of_6_30_2023_k7C6SKQheEy_MxotDp9Q1A", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PrepaidInsurance", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_vhmnjuGA6062sbON5KQrYQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40501 - Disclosure - Prepaid Expenses and Other Current Assets (Details)", "menuCat": "Details", "order": "41", "role": "http://www.petrospharma.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails", "shortName": "Prepaid Expenses and Other Current Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "ptpi:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock", "ptpi:SummaryOfPrepaidExpensesAndOtherCurrentAssetsTextBlock", "div", "div", "body", "html" ], "baseRef": "tmb-20230630x10q.htm", "contextRef": "As_Of_6_30_2023_k7C6SKQheEy_MxotDp9Q1A", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PrepaidInsurance", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_vhmnjuGA6062sbON5KQrYQ", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "tmb-20230630x10q.htm", "contextRef": "As_Of_12_31_2022_xpnCqlOw0ESb4iWj16WdvA", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsNet", "reportCount": 1, "unitRef": "Unit_Standard_USD_vhmnjuGA6062sbON5KQrYQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40601 - Disclosure - Intangible Assets (Details)", "menuCat": "Details", "order": "42", "role": "http://www.petrospharma.com/role/DisclosureIntangibleAssetsDetails", "shortName": "Intangible Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "tmb-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_bGPcSN_Lv0anGo0Q8w56yw", "decimals": "0", "lang": null, "name": "us-gaap:AmortizationOfIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_vhmnjuGA6062sbON5KQrYQ", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "tmb-20230630x10q.htm", "contextRef": "As_Of_6_30_2023_k7C6SKQheEy_MxotDp9Q1A", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_vhmnjuGA6062sbON5KQrYQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40602 - Disclosure - Intangible Assets - Future annual amortization (Details)", "menuCat": "Details", "order": "43", "role": "http://www.petrospharma.com/role/DisclosureIntangibleAssetsFutureAnnualAmortizationDetails", "shortName": "Intangible Assets - Future annual amortization (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "tmb-20230630x10q.htm", "contextRef": "As_Of_6_30_2023_k7C6SKQheEy_MxotDp9Q1A", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_vhmnjuGA6062sbON5KQrYQ", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "tmb-20230630x10q.htm", "contextRef": "As_Of_12_31_2022_xpnCqlOw0ESb4iWj16WdvA", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsNet", "reportCount": 1, "unitRef": "Unit_Standard_USD_vhmnjuGA6062sbON5KQrYQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40603 - Disclosure - Intangible Assets - Additional Information (Details)", "menuCat": "Details", "order": "44", "role": "http://www.petrospharma.com/role/DisclosureIntangibleAssetsAdditionalInformationDetails", "shortName": "Intangible Assets - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "tmb-20230630x10q.htm", "contextRef": "As_Of_6_30_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ptpi_StendraProductMember_1lsR5pni-k2ZgFZOeS7qQw", "decimals": null, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "ptpi:AccruedLiabilitiesTextBlock", "div", "div", "body", "html" ], "baseRef": "tmb-20230630x10q.htm", "contextRef": "As_Of_6_30_2023_k7C6SKQheEy_MxotDp9Q1A", "decimals": "0", "first": true, "lang": null, "name": "ptpi:AccruedProductReturns", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_vhmnjuGA6062sbON5KQrYQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40701 - Disclosure - Accrued Expenses (Details)", "menuCat": "Details", "order": "45", "role": "http://www.petrospharma.com/role/DisclosureAccruedExpensesDetails", "shortName": "Accrued Expenses (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "ptpi:AccruedLiabilitiesTextBlock", "div", "div", "body", "html" ], "baseRef": "tmb-20230630x10q.htm", "contextRef": "As_Of_6_30_2023_k7C6SKQheEy_MxotDp9Q1A", "decimals": "0", "first": true, "lang": null, "name": "ptpi:AccruedProductReturns", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_vhmnjuGA6062sbON5KQrYQ", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "p", "us-gaap:DebtDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "tmb-20230630x10q.htm", "contextRef": "As_Of_6_30_2023_us-gaap_DebtInstrumentAxis_us-gaap_NotesPayableOtherPayablesMember__oRHAMbIHUS9KbBjRu7EQw", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentFaceAmount", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_vhmnjuGA6062sbON5KQrYQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40801 - Disclosure - Debt - Promissory Note (Details)", "menuCat": "Details", "order": "46", "role": "http://www.petrospharma.com/role/DisclosureDebtPromissoryNoteDetails", "shortName": "Debt - Promissory Note (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:DebtDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "tmb-20230630x10q.htm", "contextRef": "As_Of_6_30_2023_us-gaap_DebtInstrumentAxis_us-gaap_NotesPayableOtherPayablesMember__oRHAMbIHUS9KbBjRu7EQw", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentFaceAmount", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_vhmnjuGA6062sbON5KQrYQ", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "tmb-20230630x10q.htm", "contextRef": "As_Of_6_30_2023_us-gaap_DebtInstrumentAxis_us-gaap_NotesPayableOtherPayablesMember__oRHAMbIHUS9KbBjRu7EQw", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_vhmnjuGA6062sbON5KQrYQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40802 - Disclosure - Debt - Future minimum principal payments (Details)", "menuCat": "Details", "order": "47", "role": "http://www.petrospharma.com/role/DisclosureDebtFutureMinimumPrincipalPaymentsDetails", "shortName": "Debt - Future minimum principal payments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "tmb-20230630x10q.htm", "contextRef": "As_Of_6_30_2023_us-gaap_DebtInstrumentAxis_us-gaap_NotesPayableOtherPayablesMember__oRHAMbIHUS9KbBjRu7EQw", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_vhmnjuGA6062sbON5KQrYQ", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "p", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "body", "html" ], "baseRef": "tmb-20230630x10q.htm", "contextRef": "As_Of_1_10_2022_a69_G02tkEiFJ87rv3ZWFw", "decimals": "0", "first": true, "lang": null, "name": "ptpi:SecurityDepositForSubLeaseReceived", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_vhmnjuGA6062sbON5KQrYQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40901 - Disclosure - Operating Leases - (Details)", "menuCat": "Details", "order": "48", "role": "http://www.petrospharma.com/role/DisclosureOperatingLeasesDetails", "shortName": "Operating Leases - (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "body", "html" ], "baseRef": "tmb-20230630x10q.htm", "contextRef": "As_Of_1_10_2022_a69_G02tkEiFJ87rv3ZWFw", "decimals": "0", "first": true, "lang": null, "name": "ptpi:SecurityDepositForSubLeaseReceived", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_vhmnjuGA6062sbON5KQrYQ", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "p", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "body", "html" ], "baseRef": "tmb-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_UpQ10Nz_xk-G46CtOUEocg", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_vhmnjuGA6062sbON5KQrYQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40902 - Disclosure - Operating Leases - Lease expense (Details)", "menuCat": "Details", "order": "49", "role": "http://www.petrospharma.com/role/DisclosureOperatingLeasesLeaseExpenseDetails", "shortName": "Operating Leases - Lease expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "body", "html" ], "baseRef": "tmb-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_UpQ10Nz_xk-G46CtOUEocg", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_vhmnjuGA6062sbON5KQrYQ", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "tmb-20230630x10q.htm", "contextRef": "As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_OZYRGTX5YUqy6pJtMkHu3A", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_vhmnjuGA6062sbON5KQrYQ", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY", "menuCat": "Statements", "order": "5", "role": "http://www.petrospharma.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "tmb-20230630x10q.htm", "contextRef": "As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_OZYRGTX5YUqy6pJtMkHu3A", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_vhmnjuGA6062sbON5KQrYQ", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "ptpi:LesseeOperatingLeaseSupplementalBalanceSheetInformationTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "body", "html" ], "baseRef": "tmb-20230630x10q.htm", "contextRef": "As_Of_6_30_2023_k7C6SKQheEy_MxotDp9Q1A", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_vhmnjuGA6062sbON5KQrYQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40903 - Disclosure - Operating Leases - Supplemental balance sheet information related to leases (Details)", "menuCat": "Details", "order": "50", "role": "http://www.petrospharma.com/role/DisclosureOperatingLeasesSupplementalBalanceSheetInformationRelatedToLeasesDetails", "shortName": "Operating Leases - Supplemental balance sheet information related to leases (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "ptpi:LesseeOperatingLeaseSupplementalBalanceSheetInformationTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "body", "html" ], "baseRef": "tmb-20230630x10q.htm", "contextRef": "As_Of_6_30_2023_k7C6SKQheEy_MxotDp9Q1A", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_vhmnjuGA6062sbON5KQrYQ", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "ptpi:LesseeOperatingLeaseSupplementalLeaseTermAndDiscountRateInformationTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20230630x10q.htm", "contextRef": "As_Of_6_30_2023_k7C6SKQheEy_MxotDp9Q1A", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40904 - Disclosure - Operating Leases - Supplemental lease term and discount rate information (Details)", "menuCat": "Details", "order": "51", "role": "http://www.petrospharma.com/role/DisclosureOperatingLeasesSupplementalLeaseTermAndDiscountRateInformationDetails", "shortName": "Operating Leases - Supplemental lease term and discount rate information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "ptpi:LesseeOperatingLeaseSupplementalLeaseTermAndDiscountRateInformationTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20230630x10q.htm", "contextRef": "As_Of_12_31_2022_xpnCqlOw0ESb4iWj16WdvA", "decimals": null, "lang": "en-US", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20230630x10q.htm", "contextRef": "As_Of_6_30_2023_k7C6SKQheEy_MxotDp9Q1A", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_vhmnjuGA6062sbON5KQrYQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40905 - Disclosure - Operating Leases - Future minimum lease payments under non-cancelable leases (Details)", "menuCat": "Details", "order": "52", "role": "http://www.petrospharma.com/role/DisclosureOperatingLeasesFutureMinimumLeasePaymentsUnderNonCancelableLeasesDetails", "shortName": "Operating Leases - Future minimum lease payments under non-cancelable leases (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20230630x10q.htm", "contextRef": "As_Of_6_30_2023_k7C6SKQheEy_MxotDp9Q1A", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_vhmnjuGA6062sbON5KQrYQ", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "ptpi:ScheduleOfFutureMinimumRentalPaymentsReceivableForSubLeasesTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20230630x10q.htm", "contextRef": "As_Of_6_30_2023_k7C6SKQheEy_MxotDp9Q1A", "decimals": "0", "first": true, "lang": null, "name": "ptpi:OperatingLeasesFutureMinimumPaymentsReceivableSubLeaseRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_vhmnjuGA6062sbON5KQrYQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40906 - Disclosure - Operating Leases - Future minimum sublease income under non-cancelable leases (Details)", "menuCat": "Details", "order": "53", "role": "http://www.petrospharma.com/role/DisclosureOperatingLeasesFutureMinimumSubleaseIncomeUnderNonCancelableLeasesDetails", "shortName": "Operating Leases - Future minimum sublease income under non-cancelable leases (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "ptpi:ScheduleOfFutureMinimumRentalPaymentsReceivableForSubLeasesTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20230630x10q.htm", "contextRef": "As_Of_6_30_2023_k7C6SKQheEy_MxotDp9Q1A", "decimals": "0", "first": true, "lang": null, "name": "ptpi:OperatingLeasesFutureMinimumPaymentsReceivableSubLeaseRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_vhmnjuGA6062sbON5KQrYQ", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20230630x10q.htm", "contextRef": "As_Of_6_30_2023_k7C6SKQheEy_MxotDp9Q1A", "decimals": "0", "first": true, "lang": null, "name": "ptpi:LesseeOperatingLeaseLeaseNotYetCommencedAmount", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_vhmnjuGA6062sbON5KQrYQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40907 - Disclosure - Operating Leases - Additional information (Details)", "menuCat": "Details", "order": "54", "role": "http://www.petrospharma.com/role/DisclosureOperatingLeasesAdditionalInformationDetails", "shortName": "Operating Leases - Additional information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20230630x10q.htm", "contextRef": "As_Of_6_30_2023_k7C6SKQheEy_MxotDp9Q1A", "decimals": "0", "first": true, "lang": null, "name": "ptpi:LesseeOperatingLeaseLeaseNotYetCommencedAmount", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_vhmnjuGA6062sbON5KQrYQ", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "baseRef": "tmb-20230630x10q.htm", "contextRef": "As_Of_6_30_2023_k7C6SKQheEy_MxotDp9Q1A", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_h85vs13OzkeGJCK-nyVGNg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41001 - Disclosure - Stock Options and Restricted Stock Units (\"RSU's\") (Details)", "menuCat": "Details", "order": "55", "role": "http://www.petrospharma.com/role/DisclosureStockOptionsAndRestrictedStockUnitsrsuSDetails", "shortName": "Stock Options and Restricted Stock Units (\"RSU's\") (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "baseRef": "tmb-20230630x10q.htm", "contextRef": "As_Of_6_30_2023_k7C6SKQheEy_MxotDp9Q1A", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_h85vs13OzkeGJCK-nyVGNg", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20230630x10q.htm", "contextRef": "As_Of_12_31_2022_xpnCqlOw0ESb4iWj16WdvA", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "Unit_Standard_shares_h85vs13OzkeGJCK-nyVGNg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41002 - Disclosure - Stock Options and Restricted Stock Units (\"RSU's\") - Summary of stock options (Details)", "menuCat": "Details", "order": "56", "role": "http://www.petrospharma.com/role/DisclosureStockOptionsAndRestrictedStockUnitsrsuSSummaryOfStockOptionsDetails", "shortName": "Stock Options and Restricted Stock Units (\"RSU's\") - Summary of stock options (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_bGPcSN_Lv0anGo0Q8w56yw", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_h85vs13OzkeGJCK-nyVGNg", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20230630x10q.htm", "contextRef": "Duration_4_10_2023_To_4_10_2023_rHfmgZweZkG4vB5k6zkhQw", "decimals": "INF", "first": true, "lang": null, "name": "ptpi:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfDirectorsToWhomOptionIsGranted", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_director_iPtBhf5mFkWk_k64LQu4Ww", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41003 - Disclosure - Stock Options and Restricted Stock Units (\"RSU's\") - Additional Information (Details)", "menuCat": "Details", "order": "57", "role": "http://www.petrospharma.com/role/DisclosureStockOptionsAndRestrictedStockUnitsrsuSAdditionalInformationDetails", "shortName": "Stock Options and Restricted Stock Units (\"RSU's\") - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20230630x10q.htm", "contextRef": "Duration_4_10_2023_To_4_10_2023_rHfmgZweZkG4vB5k6zkhQw", "decimals": "INF", "first": true, "lang": null, "name": "ptpi:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfDirectorsToWhomOptionIsGranted", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_director_iPtBhf5mFkWk_k64LQu4Ww", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "ptpi:ScheduleOfWarrantsAndRightsByExpirationDateTableTextBlock", "ptpi:WarrantsAndRightsNoteDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "tmb-20230630x10q.htm", "contextRef": "As_Of_6_30_2023_k7C6SKQheEy_MxotDp9Q1A", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_h85vs13OzkeGJCK-nyVGNg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41101 - Disclosure - Common Stock Warrants - Company's warrants by expiration date (Details)", "menuCat": "Details", "order": "58", "role": "http://www.petrospharma.com/role/DisclosureCommonStockWarrantsCompanySWarrantsByExpirationDateDetails", "shortName": "Common Stock Warrants - Company's warrants by expiration date (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "ptpi:ScheduleOfWarrantsAndRightsByExpirationDateTableTextBlock", "ptpi:WarrantsAndRightsNoteDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "tmb-20230630x10q.htm", "contextRef": "As_Of_6_30_2023_k7C6SKQheEy_MxotDp9Q1A", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_h85vs13OzkeGJCK-nyVGNg", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "tmb-20230630x10q.htm", "contextRef": "Duration_4_1_2023_To_6_30_2023_QgrawYbZDUmYHoreYKbCoA", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "Unit_Standard_USD_vhmnjuGA6062sbON5KQrYQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41201 - Disclosure - Basic and Diluted Net Income (Loss) per Common Share - Reconciliation of the weighted average number of common shares outstanding used in calculating basic and diluted net loss per share (Details)", "menuCat": "Details", "order": "59", "role": "http://www.petrospharma.com/role/DisclosureBasicAndDilutedNetIncomeLossPerCommonShareReconciliationOfWeightedAverageNumberOfCommonSharesOutstandingUsedInCalculatingBasicAndDilutedNetLossPerShareDetails", "shortName": "Basic and Diluted Net Income (Loss) per Common Share - Reconciliation of the weighted average number of common shares outstanding used in calculating basic and diluted net loss per share (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R6": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "tmb-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_bGPcSN_Lv0anGo0Q8w56yw", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_vhmnjuGA6062sbON5KQrYQ", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "menuCat": "Statements", "order": "6", "role": "http://www.petrospharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "tmb-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_bGPcSN_Lv0anGo0Q8w56yw", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_vhmnjuGA6062sbON5KQrYQ", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "baseRef": "tmb-20230630x10q.htm", "contextRef": "Duration_4_1_2023_To_6_30_2023_QgrawYbZDUmYHoreYKbCoA", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_h85vs13OzkeGJCK-nyVGNg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41202 - Disclosure - Basic and Diluted Net Income (Loss) per Common Share - Potentially dilutive securities convertible into common shares that were excluded from the calculation of diluted net income (loss) per share (Details)", "menuCat": "Details", "order": "60", "role": "http://www.petrospharma.com/role/DisclosureBasicAndDilutedNetIncomeLossPerCommonSharePotentiallyDilutiveSecuritiesConvertibleIntoCommonSharesThatWereExcludedFromCalculationOfDilutedNetIncomeLossPerShareDetails", "shortName": "Basic and Diluted Net Income (Loss) per Common Share - Potentially dilutive securities convertible into common shares that were excluded from the calculation of diluted net income (loss) per share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "baseRef": "tmb-20230630x10q.htm", "contextRef": "Duration_4_1_2023_To_6_30_2023_QgrawYbZDUmYHoreYKbCoA", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_h85vs13OzkeGJCK-nyVGNg", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "tmb-20230630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_HdljStn5906otR_1TlsJDA", "decimals": "0", "first": true, "lang": null, "name": "ptpi:NoncashDecreaseInAccruedExpensesRelatedToVivusSettlement", "reportCount": 1, "unitRef": "Unit_Standard_USD_vhmnjuGA6062sbON5KQrYQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41301 - Disclosure - Marketing, Licensing and Distribution Agreements - Vivus (Details)", "menuCat": "Details", "order": "61", "role": "http://www.petrospharma.com/role/DisclosureMarketingLicensingAndDistributionAgreementsVivusDetails", "shortName": "Marketing, Licensing and Distribution Agreements - Vivus (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:CollaborativeArrangementDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "tmb-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_srt_StatementScenarioAxis_ptpi_ScenarioOneMember_us-gaap_TypeOfArrangementAxis_ptpi_LicenseAgreementMember_mIP2ec2ckk-3pT5-Zwhkgw", "decimals": "-6", "lang": null, "name": "ptpi:CollaborativeArrangementThresholdNetSales", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_vhmnjuGA6062sbON5KQrYQ", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "tmb-20230630x10q.htm", "contextRef": "Duration_4_1_2023_To_6_30_2023_QgrawYbZDUmYHoreYKbCoA", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "Unit_Standard_USD_vhmnjuGA6062sbON5KQrYQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41501 - Disclosure - Segment Information (Details)", "menuCat": "Details", "order": "62", "role": "http://www.petrospharma.com/role/DisclosureSegmentInformationDetails", "shortName": "Segment Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20230630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_HdljStn5906otR_1TlsJDA", "decimals": "0", "lang": null, "name": "us-gaap:GainLossRelatedToLitigationSettlement", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_vhmnjuGA6062sbON5KQrYQ", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "tmb-20230630x10q.htm", "contextRef": "Duration_4_1_2023_To_6_30_2023_QgrawYbZDUmYHoreYKbCoA", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "Unit_Standard_USD_vhmnjuGA6062sbON5KQrYQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41502 - Disclosure - Segment Information - Net Sales by Geographic region (Details)", "menuCat": "Details", "order": "63", "role": "http://www.petrospharma.com/role/DisclosureSegmentInformationNetSalesByGeographicRegionDetails", "shortName": "Segment Information - Net Sales by Geographic region (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20230630x10q.htm", "contextRef": "Duration_4_1_2023_To_6_30_2023_srt_StatementGeographicalAxis_country_US_aGCsUANt0kWE5iYMsMc4Mg", "decimals": "0", "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_vhmnjuGA6062sbON5KQrYQ", "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "tmb-20230630x10q.htm", "contextRef": "As_Of_6_30_2023_k7C6SKQheEy_MxotDp9Q1A", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:IntangibleAssetsNetExcludingGoodwill", "reportCount": 1, "unitRef": "Unit_Standard_USD_vhmnjuGA6062sbON5KQrYQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41503 - Disclosure - Segment Information - Segment assets (Details)", "menuCat": "Details", "order": "64", "role": "http://www.petrospharma.com/role/DisclosureSegmentInformationSegmentAssetsDetails", "shortName": "Segment Information - Segment assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20230630x10q.htm", "contextRef": "As_Of_6_30_2023_us-gaap_StatementBusinessSegmentsAxis_ptpi_PrescriptionMedicationSalesMember_mZ2CWmwq0kGL_VF98tD9pA", "decimals": "0", "lang": null, "name": "us-gaap:IntangibleAssetsNetExcludingGoodwill", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_vhmnjuGA6062sbON5KQrYQ", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "tmb-20230630x10q.htm", "contextRef": "As_Of_6_30_2023_k7C6SKQheEy_MxotDp9Q1A", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unitRef": "Unit_Divide_USD_shares_4ILe2HwoJkSuKGzbAHXCkA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41601 - Disclosure - Subsequent Events (Details)", "menuCat": "Details", "order": "65", "role": "http://www.petrospharma.com/role/DisclosureSubsequentEventsDetails", "shortName": "Subsequent Events (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20230630x10q.htm", "contextRef": "As_Of_7_13_2023_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_fFcQdHvcBUWOPgIITeJJCg", "decimals": "2", "lang": null, "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "reportCount": 1, "unique": true, "unitRef": "Unit_Divide_USD_shares_4ILe2HwoJkSuKGzbAHXCkA", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "tmb-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_bGPcSN_Lv0anGo0Q8w56yw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10101 - Disclosure - Nature of Operations, Basis of Presentation, Liquidity and Going Concern", "menuCat": "Notes", "order": "7", "role": "http://www.petrospharma.com/role/DisclosureNatureOfOperationsBasisOfPresentationLiquidityAndGoingConcern", "shortName": "Nature of Operations, Basis of Presentation, Liquidity and Going Concern", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "tmb-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_bGPcSN_Lv0anGo0Q8w56yw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "tmb-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_bGPcSN_Lv0anGo0Q8w56yw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10201 - Disclosure - Summary of Significant Accounting Policies", "menuCat": "Notes", "order": "8", "role": "http://www.petrospharma.com/role/DisclosureSummaryOfSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "tmb-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_bGPcSN_Lv0anGo0Q8w56yw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "tmb-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_bGPcSN_Lv0anGo0Q8w56yw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LoansNotesTradeAndOtherReceivablesExcludingAllowanceForCreditLossesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10301 - Disclosure - Accounts Receivable, net", "menuCat": "Notes", "order": "9", "role": "http://www.petrospharma.com/role/DisclosureAccountsReceivableNet", "shortName": "Accounts Receivable, net", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "tmb-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_bGPcSN_Lv0anGo0Q8w56yw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LoansNotesTradeAndOtherReceivablesExcludingAllowanceForCreditLossesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 67, "tag": { "country_US": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "United States" } } }, "localname": "US", "nsuri": "http://xbrl.sec.gov/country/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureSegmentInformationNetSalesByGeographicRegionDetails" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.petrospharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.petrospharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Document and Entity Information" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2023", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.petrospharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.petrospharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.petrospharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.petrospharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r616" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.petrospharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r617" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.petrospharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.petrospharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.petrospharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.petrospharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.petrospharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.petrospharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.petrospharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r614" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.petrospharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.petrospharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.petrospharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r614" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.petrospharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r619" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.petrospharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.petrospharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r614" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.petrospharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.petrospharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r618" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.petrospharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r614" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.petrospharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r614" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.petrospharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r614" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.petrospharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r614" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.petrospharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.petrospharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r613" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.petrospharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r615" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.petrospharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.petrospharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "ptpi_AccountsReceivableCashDiscountAllowances": { "auth_ref": [], "calculation": { "http://www.petrospharma.com/role/DisclosureAccountsReceivableNetDetails": { "order": 3.0, "parentTag": "us-gaap_AccountsReceivableNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash discount allowances on accounts receivable.", "label": "Accounts Receivable, Cash Discount Allowances", "negatedLabel": "Cash discount allowances" } } }, "localname": "AccountsReceivableCashDiscountAllowances", "nsuri": "http://www.petrospharma.com/20230630", "presentation": [ "http://www.petrospharma.com/role/DisclosureAccountsReceivableNetDetails" ], "xbrltype": "monetaryItemType" }, "ptpi_AccountsReceivableChargebacksAccruals": { "auth_ref": [], "calculation": { "http://www.petrospharma.com/role/DisclosureAccountsReceivableNetDetails": { "order": 4.0, "parentTag": "us-gaap_AccountsReceivableNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for chargebacks accruals on accounts receivable.", "label": "Accounts Receivable, Chargebacks Accruals", "negatedLabel": "Chargebacks accrual" } } }, "localname": "AccountsReceivableChargebacksAccruals", "nsuri": "http://www.petrospharma.com/20230630", "presentation": [ "http://www.petrospharma.com/role/DisclosureAccountsReceivableNetDetails" ], "xbrltype": "monetaryItemType" }, "ptpi_AccountsReceivableDistributionServiceFees": { "auth_ref": [], "calculation": { "http://www.petrospharma.com/role/DisclosureAccountsReceivableNetDetails": { "order": 5.0, "parentTag": "us-gaap_AccountsReceivableNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for distribution service fees on accounts receivable.", "label": "Accounts Receivable, Distribution Service Fees", "negatedLabel": "Distribution service fees" } } }, "localname": "AccountsReceivableDistributionServiceFees", "nsuri": "http://www.petrospharma.com/20230630", "presentation": [ "http://www.petrospharma.com/role/DisclosureAccountsReceivableNetDetails" ], "xbrltype": "monetaryItemType" }, "ptpi_AccruedContractRebates": { "auth_ref": [], "calculation": { "http://www.petrospharma.com/role/DisclosureAccruedExpensesDetails": { "order": 1.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for contract rebates Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Contract Rebates", "terseLabel": "Accrued contract rebates" } } }, "localname": "AccruedContractRebates", "nsuri": "http://www.petrospharma.com/20230630", "presentation": [ "http://www.petrospharma.com/role/DisclosureAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "ptpi_AccruedExpenseTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Na.", "label": "Accrued Expense [Table]" } } }, "localname": "AccruedExpenseTable", "nsuri": "http://www.petrospharma.com/20230630", "presentation": [ "http://www.petrospharma.com/role/DisclosureAccruedExpensesDetails" ], "xbrltype": "stringItemType" }, "ptpi_AccruedExpensesLineItem": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Na.", "label": "Accrued Expenses [Line Item]", "verboseLabel": "Accrued Expenses" } } }, "localname": "AccruedExpensesLineItem", "nsuri": "http://www.petrospharma.com/20230630", "presentation": [ "http://www.petrospharma.com/role/DisclosureAccruedExpensesDetails" ], "xbrltype": "stringItemType" }, "ptpi_AccruedLiabilitiesTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure on accrued liabilities.", "label": "Accrued Liabilities [Text Block]", "terseLabel": "Accrued Expenses" } } }, "localname": "AccruedLiabilitiesTextBlock", "nsuri": "http://www.petrospharma.com/20230630", "presentation": [ "http://www.petrospharma.com/role/DisclosureAccruedExpenses" ], "xbrltype": "textBlockItemType" }, "ptpi_AccruedProductReturns": { "auth_ref": [], "calculation": { "http://www.petrospharma.com/role/DisclosureAccruedExpensesDetails": { "order": 2.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for product returns. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Product Returns", "terseLabel": "Accrued product returns" } } }, "localname": "AccruedProductReturns", "nsuri": "http://www.petrospharma.com/20230630", "presentation": [ "http://www.petrospharma.com/role/DisclosureAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "ptpi_AdjustmentsForDeferredRevenue": { "auth_ref": [], "calculation": { "http://www.petrospharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of adjustments charged against deferred revenue during the period.", "label": "Adjustments for Deferred Revenue", "terseLabel": "Deferred revenue" } } }, "localname": "AdjustmentsForDeferredRevenue", "nsuri": "http://www.petrospharma.com/20230630", "presentation": [ "http://www.petrospharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ptpi_AggregateSharesOfPreferredStockAgreedToSell": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of aggregate shares of preferred stock agreed to sell.", "label": "Aggregate Shares of Preferred Stock Agreed to Sell", "terseLabel": "Aggregate shares agreed to sell" } } }, "localname": "AggregateSharesOfPreferredStockAgreedToSell", "nsuri": "http://www.petrospharma.com/20230630", "presentation": [ "http://www.petrospharma.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "sharesItemType" }, "ptpi_ApiInventoryRetained": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the amount due under agreement. The amount of API inventory retained.", "label": "API Inventory Retained", "terseLabel": "Inventory amount retained - API" } } }, "localname": "ApiInventoryRetained", "nsuri": "http://www.petrospharma.com/20230630", "presentation": [ "http://www.petrospharma.com/role/DisclosureMarketingLicensingAndDistributionAgreementsVivusDetails" ], "xbrltype": "monetaryItemType" }, "ptpi_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Cash Paid For Amounts Included In Measurement of Lease Liabilities [Abstract]", "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities:" } } }, "localname": "CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract", "nsuri": "http://www.petrospharma.com/20230630", "presentation": [ "http://www.petrospharma.com/role/DisclosureOperatingLeasesSupplementalLeaseTermAndDiscountRateInformationDetails" ], "xbrltype": "stringItemType" }, "ptpi_CollaborativeArrangementAccruedInventoryPurchasesOtherAssets": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the amount of accrued inventory purchases as of balance sheet date, classified as other assets.", "label": "Collaborative Arrangement Accrued Inventory Purchases Other Assets", "terseLabel": "Accrued inventory purchases, other assets" } } }, "localname": "CollaborativeArrangementAccruedInventoryPurchasesOtherAssets", "nsuri": "http://www.petrospharma.com/20230630", "presentation": [ "http://www.petrospharma.com/role/DisclosureMarketingLicensingAndDistributionAgreementsVivusDetails" ], "xbrltype": "monetaryItemType" }, "ptpi_CollaborativeArrangementInventoryRawMaterial": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the amount of inventory classified as raw materials in collaborative arrangement.", "label": "Collaborative Arrangement, Inventory, Raw Material", "terseLabel": "Raw materials inventory" } } }, "localname": "CollaborativeArrangementInventoryRawMaterial", "nsuri": "http://www.petrospharma.com/20230630", "presentation": [ "http://www.petrospharma.com/role/DisclosureMarketingLicensingAndDistributionAgreementsVivusDetails" ], "xbrltype": "monetaryItemType" }, "ptpi_CollaborativeArrangementMilestonePaymentPayable": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the amount of milestone payment payable.", "label": "Collaborative Arrangement, Milestone Payment Payable", "terseLabel": "Milestone payment" } } }, "localname": "CollaborativeArrangementMilestonePaymentPayable", "nsuri": "http://www.petrospharma.com/20230630", "presentation": [ "http://www.petrospharma.com/role/DisclosureMarketingLicensingAndDistributionAgreementsVivusDetails" ], "xbrltype": "monetaryItemType" }, "ptpi_CollaborativeArrangementOneTimeFees": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the amount of one-time fee to purchase and receive the license for the commercialization and exploitation of Stendra", "label": "Collaborative Arrangement, One Time Fees", "terseLabel": "One-time fee to purchase and receive the license for the commercialization and exploitation of Stendra" } } }, "localname": "CollaborativeArrangementOneTimeFees", "nsuri": "http://www.petrospharma.com/20230630", "presentation": [ "http://www.petrospharma.com/role/DisclosureMarketingLicensingAndDistributionAgreementsVivusDetails" ], "xbrltype": "monetaryItemType" }, "ptpi_CollaborativeArrangementRoyaltyPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the percentage of royalty.", "label": "Collaborative Arrangement, Royalty Percentage", "terseLabel": "Royalty percentage" } } }, "localname": "CollaborativeArrangementRoyaltyPercentage", "nsuri": "http://www.petrospharma.com/20230630", "presentation": [ "http://www.petrospharma.com/role/DisclosureMarketingLicensingAndDistributionAgreementsVivusDetails" ], "xbrltype": "percentItemType" }, "ptpi_CollaborativeArrangementThresholdNetSales": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the threshold net sales.", "label": "Collaborative Arrangement, Threshold Net Sales", "terseLabel": "Threshold net sales" } } }, "localname": "CollaborativeArrangementThresholdNetSales", "nsuri": "http://www.petrospharma.com/20230630", "presentation": [ "http://www.petrospharma.com/role/DisclosureMarketingLicensingAndDistributionAgreementsVivusDetails" ], "xbrltype": "monetaryItemType" }, "ptpi_CommonStockClosingPricePerShareLimitForConversionOfStockFor20ConsecutiveTradingDays": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common stock closing price per share limit for conversion of stock for 20 consecutive trading days.", "label": "Common Stock Closing Price Per Share Limit for Conversion of Stock for 20 Consecutive Trading Days", "terseLabel": "Common stock closing price per share limit for conversion of stock for 20 consecutive trading days" } } }, "localname": "CommonStockClosingPricePerShareLimitForConversionOfStockFor20ConsecutiveTradingDays", "nsuri": "http://www.petrospharma.com/20230630", "presentation": [ "http://www.petrospharma.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "perShareItemType" }, "ptpi_ContractWithCustomerRightToReturnAndReceiveCreditForProduct": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the right to return and receive credit for product.", "label": "Contract With Customer, Right to Return and Receive Credit for Product", "terseLabel": "Right to return and receive credit for product" } } }, "localname": "ContractWithCustomerRightToReturnAndReceiveCreditForProduct", "nsuri": "http://www.petrospharma.com/20230630", "presentation": [ "http://www.petrospharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "durationItemType" }, "ptpi_ContractWithCustomerSalesDeduction": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the reserves for sales deductions.", "label": "Contract With Customer, Sales Deduction", "terseLabel": "Reserves for sales deductions" } } }, "localname": "ContractWithCustomerSalesDeduction", "nsuri": "http://www.petrospharma.com/20230630", "presentation": [ "http://www.petrospharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "ptpi_ConversionPriceForValuationOfCommonStock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Conversion price for valuation of common stock.", "label": "Conversion Price For Valuation of Common Stock", "terseLabel": "Conversion price for valuation of common stock" } } }, "localname": "ConversionPriceForValuationOfCommonStock", "nsuri": "http://www.petrospharma.com/20230630", "presentation": [ "http://www.petrospharma.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "perShareItemType" }, "ptpi_DailyDollarTradingVolumeOfCommonStockLimitForConversionOfStock": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Daily dollar trading volume of common stock limit for conversion of stock.", "label": "Daily Dollar Trading Volume of Common Stock Limit for Conversion of Stock", "terseLabel": "Daily dollar trading volume of common stock limit for conversion of stock" } } }, "localname": "DailyDollarTradingVolumeOfCommonStockLimitForConversionOfStock", "nsuri": "http://www.petrospharma.com/20230630", "presentation": [ "http://www.petrospharma.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "ptpi_DebtInstrumentDebtDefaultInterestRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the interest rate at the time of default.", "label": "Debt Instrument, Debt Default, Interest Rate", "terseLabel": "Interest rate at the time of default (in percent)" } } }, "localname": "DebtInstrumentDebtDefaultInterestRate", "nsuri": "http://www.petrospharma.com/20230630", "presentation": [ "http://www.petrospharma.com/role/DisclosureDebtPromissoryNoteDetails" ], "xbrltype": "percentItemType" }, "ptpi_DomesticCustomersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to domestic customers.", "label": "Domestic customers" } } }, "localname": "DomesticCustomersMember", "nsuri": "http://www.petrospharma.com/20230630", "presentation": [ "http://www.petrospharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "ptpi_DuePeriodForInvoicePayments": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the due period for invoice payments.", "label": "Due Period for Invoice Payments", "terseLabel": "Due period for invoice payments" } } }, "localname": "DuePeriodForInvoicePayments", "nsuri": "http://www.petrospharma.com/20230630", "presentation": [ "http://www.petrospharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "durationItemType" }, "ptpi_DueToThirdPartyLogisticProvider": { "auth_ref": [], "calculation": { "http://www.petrospharma.com/role/DisclosureAccruedExpensesDetails": { "order": 5.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for third-party logistic provider. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Due to Third-party Logistic Provider", "terseLabel": "Due to 3PL/Wholesalers" } } }, "localname": "DueToThirdPartyLogisticProvider", "nsuri": "http://www.petrospharma.com/20230630", "presentation": [ "http://www.petrospharma.com/role/DisclosureAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "ptpi_ExpirationDateOfAugust232023Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the Expiration Date of August 23, 2023.", "label": "Expiration Date of August 23, 2023" } } }, "localname": "ExpirationDateOfAugust232023Member", "nsuri": "http://www.petrospharma.com/20230630", "presentation": [ "http://www.petrospharma.com/role/DisclosureCommonStockWarrantsCompanySWarrantsByExpirationDateDetails" ], "xbrltype": "domainItemType" }, "ptpi_ExpirationDateOfDecember12024Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the Expiration Date of December 1, 2024.", "label": "Expiration Date of December 1, 2024" } } }, "localname": "ExpirationDateOfDecember12024Member", "nsuri": "http://www.petrospharma.com/20230630", "presentation": [ "http://www.petrospharma.com/role/DisclosureCommonStockWarrantsCompanySWarrantsByExpirationDateDetails" ], "xbrltype": "domainItemType" }, "ptpi_ExpirationDateOfDecember12025FiveMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the Expiration Date of December 1, 2025, Five.", "label": "Expiration Date of December 1, 2025, Five" } } }, "localname": "ExpirationDateOfDecember12025FiveMember", "nsuri": "http://www.petrospharma.com/20230630", "presentation": [ "http://www.petrospharma.com/role/DisclosureCommonStockWarrantsCompanySWarrantsByExpirationDateDetails" ], "xbrltype": "domainItemType" }, "ptpi_ExpirationDateOfDecember12025FourMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the Expiration Date of December 1, 2025, Four.", "label": "Expiration Date of December 1, 2025, Four" } } }, "localname": "ExpirationDateOfDecember12025FourMember", "nsuri": "http://www.petrospharma.com/20230630", "presentation": [ "http://www.petrospharma.com/role/DisclosureCommonStockWarrantsCompanySWarrantsByExpirationDateDetails" ], "xbrltype": "domainItemType" }, "ptpi_ExpirationDateOfDecember12025OneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the Expiration Date of December 1, 2025, One.", "label": "Expiration Date of December 1, 2025, One" } } }, "localname": "ExpirationDateOfDecember12025OneMember", "nsuri": "http://www.petrospharma.com/20230630", "presentation": [ "http://www.petrospharma.com/role/DisclosureCommonStockWarrantsCompanySWarrantsByExpirationDateDetails" ], "xbrltype": "domainItemType" }, "ptpi_ExpirationDateOfDecember12025ThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the Expiration Date of December 1, 2025, Three.", "label": "Expiration Date of December 1, 2025, Three" } } }, "localname": "ExpirationDateOfDecember12025ThreeMember", "nsuri": "http://www.petrospharma.com/20230630", "presentation": [ "http://www.petrospharma.com/role/DisclosureCommonStockWarrantsCompanySWarrantsByExpirationDateDetails" ], "xbrltype": "domainItemType" }, "ptpi_ExpirationDateOfDecember12025TwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the Expiration Date of December 1, 2025, Two.", "label": "Expiration Date of December 1, 2025, Two" } } }, "localname": "ExpirationDateOfDecember12025TwoMember", "nsuri": "http://www.petrospharma.com/20230630", "presentation": [ "http://www.petrospharma.com/role/DisclosureCommonStockWarrantsCompanySWarrantsByExpirationDateDetails" ], "xbrltype": "domainItemType" }, "ptpi_ExpirationDateOfDecember122026Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the Expiration Date of December 12, 2026", "label": "Expiration Date of December 12, 2026" } } }, "localname": "ExpirationDateOfDecember122026Member", "nsuri": "http://www.petrospharma.com/20230630", "presentation": [ "http://www.petrospharma.com/role/DisclosureCommonStockWarrantsCompanySWarrantsByExpirationDateDetails" ], "xbrltype": "domainItemType" }, "ptpi_ExpirationDateOfDecember272026Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the Expiration Date of December 27, 2026.", "label": "Expiration Date of December 27, 2026" } } }, "localname": "ExpirationDateOfDecember272026Member", "nsuri": "http://www.petrospharma.com/20230630", "presentation": [ "http://www.petrospharma.com/role/DisclosureCommonStockWarrantsCompanySWarrantsByExpirationDateDetails" ], "xbrltype": "domainItemType" }, "ptpi_ExpirationDateOfJune12024Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the Expiration Date of June 1, 2024.", "label": "Expiration Date of June 1, 2024" } } }, "localname": "ExpirationDateOfJune12024Member", "nsuri": "http://www.petrospharma.com/20230630", "presentation": [ "http://www.petrospharma.com/role/DisclosureCommonStockWarrantsCompanySWarrantsByExpirationDateDetails" ], "xbrltype": "domainItemType" }, "ptpi_ExpirationDateOfJune12025Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the Expiration Date of June 1, 2025.", "label": "Expiration Date of June 1, 2025" } } }, "localname": "ExpirationDateOfJune12025Member", "nsuri": "http://www.petrospharma.com/20230630", "presentation": [ "http://www.petrospharma.com/role/DisclosureCommonStockWarrantsCompanySWarrantsByExpirationDateDetails" ], "xbrltype": "domainItemType" }, "ptpi_ExpirationDateOfJune172024Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the Expiration Date of June 17, 2024.", "label": "Expiration Date of June 17, 2024" } } }, "localname": "ExpirationDateOfJune172024Member", "nsuri": "http://www.petrospharma.com/20230630", "presentation": [ "http://www.petrospharma.com/role/DisclosureCommonStockWarrantsCompanySWarrantsByExpirationDateDetails" ], "xbrltype": "domainItemType" }, "ptpi_ExpirationDateOfJune192024Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the Expiration Date of June 19, 2024.", "label": "Expiration Date of June 19, 2024" } } }, "localname": "ExpirationDateOfJune192024Member", "nsuri": "http://www.petrospharma.com/20230630", "presentation": [ "http://www.petrospharma.com/role/DisclosureCommonStockWarrantsCompanySWarrantsByExpirationDateDetails" ], "xbrltype": "domainItemType" }, "ptpi_ExpirationDateOfMarch22025Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the Expiration Date of March 2, 2025.", "label": "Expiration Date of March 2, 2025" } } }, "localname": "ExpirationDateOfMarch22025Member", "nsuri": "http://www.petrospharma.com/20230630", "presentation": [ "http://www.petrospharma.com/role/DisclosureCommonStockWarrantsCompanySWarrantsByExpirationDateDetails" ], "xbrltype": "domainItemType" }, "ptpi_ExpirationDateOfOctober182026Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the Expiration Date of October 18, 2026.", "label": "Expiration Date of October 18, 2026" } } }, "localname": "ExpirationDateOfOctober182026Member", "nsuri": "http://www.petrospharma.com/20230630", "presentation": [ "http://www.petrospharma.com/role/DisclosureCommonStockWarrantsCompanySWarrantsByExpirationDateDetails" ], "xbrltype": "domainItemType" }, "ptpi_ExpirationDateOfSeptember12024Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the Expiration Date of September 1, 2024.", "label": "Expiration Date of September 1, 2024" } } }, "localname": "ExpirationDateOfSeptember12024Member", "nsuri": "http://www.petrospharma.com/20230630", "presentation": [ "http://www.petrospharma.com/role/DisclosureCommonStockWarrantsCompanySWarrantsByExpirationDateDetails" ], "xbrltype": "domainItemType" }, "ptpi_ExpirationDateOfSeptember12025Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the Expiration Date of September 1, 2025.", "label": "Expiration Date of September 1, 2025" } } }, "localname": "ExpirationDateOfSeptember12025Member", "nsuri": "http://www.petrospharma.com/20230630", "presentation": [ "http://www.petrospharma.com/role/DisclosureCommonStockWarrantsCompanySWarrantsByExpirationDateDetails" ], "xbrltype": "domainItemType" }, "ptpi_ExpirationDateOfSeptember162024Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the Expiration Date of September 16, 2024.", "label": "Expiration Date of September 16, 2024" } } }, "localname": "ExpirationDateOfSeptember162024Member", "nsuri": "http://www.petrospharma.com/20230630", "presentation": [ "http://www.petrospharma.com/role/DisclosureCommonStockWarrantsCompanySWarrantsByExpirationDateDetails" ], "xbrltype": "domainItemType" }, "ptpi_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour": { "auth_ref": [], "calculation": { "http://www.petrospharma.com/role/DisclosureIntangibleAssetsFutureAnnualAmortizationDetails": { "order": 6.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after four fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Four", "terseLabel": "Thereafter" } } }, "localname": "FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour", "nsuri": "http://www.petrospharma.com/20230630", "presentation": [ "http://www.petrospharma.com/role/DisclosureIntangibleAssetsFutureAnnualAmortizationDetails" ], "xbrltype": "monetaryItemType" }, "ptpi_FourCustomersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to four customers.", "label": "Four customers" } } }, "localname": "FourCustomersMember", "nsuri": "http://www.petrospharma.com/20230630", "presentation": [ "http://www.petrospharma.com/role/DisclosureAccountsReceivableNetAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "ptpi_GainLossOnSettlementWithVivus": { "auth_ref": [], "calculation": { "http://www.petrospharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://www.petrospharma.com/role/StatementCondensedConsolidatedStatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_OperatingExpenses", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of gain (loss) on settlement with Vivus.", "label": "Gain Loss on Settlement with Vivus", "negatedLabel": "Gain on settlement with Vivus", "terseLabel": "Gain on settlement with Vivus" } } }, "localname": "GainLossOnSettlementWithVivus", "nsuri": "http://www.petrospharma.com/20230630", "presentation": [ "http://www.petrospharma.com/role/DisclosureMarketingLicensingAndDistributionAgreementsVivusDetails", "http://www.petrospharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "http://www.petrospharma.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "ptpi_InterestExpenseOnPromissoryNotes": { "auth_ref": [], "calculation": { "http://www.petrospharma.com/role/StatementCondensedConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of promissory notes accounted for as interest expense for debt.", "label": "Interest Expense on Promissory Notes", "negatedLabel": "Interest expense, promissory note" } } }, "localname": "InterestExpenseOnPromissoryNotes", "nsuri": "http://www.petrospharma.com/20230630", "presentation": [ "http://www.petrospharma.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "ptpi_InternationalCustomersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to international customers.", "label": "International Customers", "terseLabel": "International customers" } } }, "localname": "InternationalCustomersMember", "nsuri": "http://www.petrospharma.com/20230630", "presentation": [ "http://www.petrospharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "ptpi_InventoryAndSampleInventoryReserve": { "auth_ref": [], "calculation": { "http://www.petrospharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of inventory and sample inventory reserve.", "label": "Inventory and Sample Inventory Reserve", "verboseLabel": "Inventory and sample inventory reserve" } } }, "localname": "InventoryAndSampleInventoryReserve", "nsuri": "http://www.petrospharma.com/20230630", "presentation": [ "http://www.petrospharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ptpi_InventoryFinishedGoodsValuationReserves": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.", "label": "Inventory, Finished Goods, Valuation Reserves", "verboseLabel": "Finished goods are net of valuation reserves" } } }, "localname": "InventoryFinishedGoodsValuationReserves", "nsuri": "http://www.petrospharma.com/20230630", "presentation": [ "http://www.petrospharma.com/role/DisclosureInventoriesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ptpi_InventoryRawMaterialsValuationReserves": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.", "label": "Inventory, Raw Materials, Valuation Reserves", "verboseLabel": "Raw materials are net of valuation reserves" } } }, "localname": "InventoryRawMaterialsValuationReserves", "nsuri": "http://www.petrospharma.com/20230630", "presentation": [ "http://www.petrospharma.com/role/DisclosureInventoriesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ptpi_KatalystSecuritiesLlcMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to Katalyst Securities LLC.", "label": "Katalyst Securities LLC [Member]", "terseLabel": "Placement Agent" } } }, "localname": "KatalystSecuritiesLlcMember", "nsuri": "http://www.petrospharma.com/20230630", "presentation": [ "http://www.petrospharma.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "ptpi_LesseeOperatingLeaseLeaseNotYetCommencedAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the amount of operating leases that had not yet commenced.", "label": "Lessee, Operating Lease, Lease Not yet Commenced, Amount", "terseLabel": "Operating leases that had not yet commenced" } } }, "localname": "LesseeOperatingLeaseLeaseNotYetCommencedAmount", "nsuri": "http://www.petrospharma.com/20230630", "presentation": [ "http://www.petrospharma.com/role/DisclosureOperatingLeasesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ptpi_LesseeOperatingLeaseSupplementalBalanceSheetInformationTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The tabular disclosure of supplemental balance sheet information related to leases.", "label": "Lessee, Operating Lease, Supplemental Balance Sheet Information [Table Text Block]", "terseLabel": "Summary of supplemental balance sheet information related to leases" } } }, "localname": "LesseeOperatingLeaseSupplementalBalanceSheetInformationTableTextBlock", "nsuri": "http://www.petrospharma.com/20230630", "presentation": [ "http://www.petrospharma.com/role/DisclosureOperatingLeasesTables" ], "xbrltype": "textBlockItemType" }, "ptpi_LesseeOperatingLeaseSupplementalCashFlowInformationTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The tabular disclosure of supplemental cash flow information related to leases.", "label": "Lessee, Operating Lease, Supplemental Cash Flow Information [Table Text Block]", "terseLabel": "Summary of supplemental cash flow information related to leases" } } }, "localname": "LesseeOperatingLeaseSupplementalCashFlowInformationTableTextBlock", "nsuri": "http://www.petrospharma.com/20230630", "presentation": [ "http://www.petrospharma.com/role/DisclosureOperatingLeasesTables" ], "xbrltype": "textBlockItemType" }, "ptpi_LesseeOperatingLeaseSupplementalLeaseTermAndDiscountRateInformationTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The tabular disclosure of supplemental lease term and discount rate information related to leases.", "label": "Lessee, Operating Lease, Supplemental Lease Term And Discount Rate Information [Table Text Block]", "terseLabel": "Summary of supplemental lease term and discount rate information related to leases" } } }, "localname": "LesseeOperatingLeaseSupplementalLeaseTermAndDiscountRateInformationTableTextBlock", "nsuri": "http://www.petrospharma.com/20230630", "presentation": [ "http://www.petrospharma.com/role/DisclosureOperatingLeasesTables" ], "xbrltype": "textBlockItemType" }, "ptpi_LicenseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to license agreement.", "label": "License Agreement", "terseLabel": "License Agreement" } } }, "localname": "LicenseAgreementMember", "nsuri": "http://www.petrospharma.com/20230630", "presentation": [ "http://www.petrospharma.com/role/DisclosureMarketingLicensingAndDistributionAgreementsVivusDetails" ], "xbrltype": "domainItemType" }, "ptpi_MarketingLicensingAndDistributionAgreementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Marketing, Licensing and Distribution Agreements." } } }, "localname": "MarketingLicensingAndDistributionAgreementsAbstract", "nsuri": "http://www.petrospharma.com/20230630", "xbrltype": "stringItemType" }, "ptpi_MaximumPercentageOfOutstandingSharesApprovedForIssuanceInAccordanceWithNasdaqStockMarketRules": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Maximum percentage of outstanding shares approved for issuance in accordance with Nasdaq stock market rules", "label": "Maximum Percentage of Outstanding Shares Approved for Issuance in Accordance with Nasdaq Stock Market Rules", "terseLabel": "Maximum percentage of outstanding shares approved for issuance in accordance with Nasdaq stock market rules" } } }, "localname": "MaximumPercentageOfOutstandingSharesApprovedForIssuanceInAccordanceWithNasdaqStockMarketRules", "nsuri": "http://www.petrospharma.com/20230630", "presentation": [ "http://www.petrospharma.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "percentItemType" }, "ptpi_MedicalDeviceSalesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to medical device sales.", "label": "Medical Devices" } } }, "localname": "MedicalDeviceSalesMember", "nsuri": "http://www.petrospharma.com/20230630", "presentation": [ "http://www.petrospharma.com/role/DisclosureSegmentInformationDetails", "http://www.petrospharma.com/role/DisclosureSegmentInformationSegmentAssetsDetails", "http://www.petrospharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "ptpi_MinimumTradingDaysAfterDateThatInitialRegistrationStatementForConsideringFirstTradingDayOfCalendarMonth": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Minimum trading days after the date that initial registration statement for considering first trading day of the calendar month.", "label": "Minimum Trading Days After the Date That Initial Registration Statement For Considering First Trading Day of The Calendar Month", "terseLabel": "Minimum trading days after the date that initial registration statement for considering first trading day of the calendar month" } } }, "localname": "MinimumTradingDaysAfterDateThatInitialRegistrationStatementForConsideringFirstTradingDayOfCalendarMonth", "nsuri": "http://www.petrospharma.com/20230630", "presentation": [ "http://www.petrospharma.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "durationItemType" }, "ptpi_MitsubishiTanabePharmaCorporationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Mitsubishi Tanabe Pharma Corporation.", "label": "MTPC", "terseLabel": "MTPC" } } }, "localname": "MitsubishiTanabePharmaCorporationMember", "nsuri": "http://www.petrospharma.com/20230630", "presentation": [ "http://www.petrospharma.com/role/DisclosureMarketingLicensingAndDistributionAgreementsVivusDetails" ], "xbrltype": "domainItemType" }, "ptpi_NatureOfOperationsBasisOfPresentationAndLiquidityLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Nature of Operations, Basis of Presentation, and Liquidity [Line Items]", "terseLabel": "Nature of Operations, Basis of Presentation, Liquidity and Going Concern" } } }, "localname": "NatureOfOperationsBasisOfPresentationAndLiquidityLineItems", "nsuri": "http://www.petrospharma.com/20230630", "presentation": [ "http://www.petrospharma.com/role/DisclosureNatureOfOperationsBasisOfPresentationLiquidityAndGoingConcernAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "ptpi_NatureOfOperationsBasisOfPresentationAndLiquidityTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of nature of operations, basis of presentation, and liquidity.", "label": "Nature of Operations, Basis of Presentation, and Liquidity [Table]" } } }, "localname": "NatureOfOperationsBasisOfPresentationAndLiquidityTable", "nsuri": "http://www.petrospharma.com/20230630", "presentation": [ "http://www.petrospharma.com/role/DisclosureNatureOfOperationsBasisOfPresentationLiquidityAndGoingConcernAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "ptpi_NonCashAcquisitionActivePharmaceuticalIngredientOfPurchaseAgreement": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of inventory that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Non cash Acquisition Active Pharmaceutical Ingredient Of Purchase Agreement", "negatedLabel": "Noncash increase in inventory due to API reclass" } } }, "localname": "NonCashAcquisitionActivePharmaceuticalIngredientOfPurchaseAgreement", "nsuri": "http://www.petrospharma.com/20230630", "presentation": [ "http://www.petrospharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ptpi_NoncashDecreaseInAccruedExpensesRelatedToVivusSettlement": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash decrease in accrued expenses related to Vivus settlement.", "label": "Noncash Decrease In Accrued Expenses Related To Vivus Settlement", "terseLabel": "Noncash decrease in accrued expenses related to Vivus settlement" } } }, "localname": "NoncashDecreaseInAccruedExpensesRelatedToVivusSettlement", "nsuri": "http://www.petrospharma.com/20230630", "presentation": [ "http://www.petrospharma.com/role/DisclosureMarketingLicensingAndDistributionAgreementsVivusDetails", "http://www.petrospharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ptpi_NoncashDecreaseInAccruedInventoryPurchasesRelatedToVivusSettlement": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash decrease in accrued inventory purchases related to Vivus settlement .", "label": "Noncash Decrease In Accrued Inventory Purchases Related To Vivus Settlement", "terseLabel": "Noncash decrease in accrued inventory purchases related to Vivus Settlement" } } }, "localname": "NoncashDecreaseInAccruedInventoryPurchasesRelatedToVivusSettlement", "nsuri": "http://www.petrospharma.com/20230630", "presentation": [ "http://www.petrospharma.com/role/DisclosureMarketingLicensingAndDistributionAgreementsVivusDetails", "http://www.petrospharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ptpi_NoncashDecreaseInApiPurchaseCommitmentRelatedToVivusSettlement": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash decrease in API purchase commitment related to Vivus settlement", "label": "Noncash Decrease In API Purchase Commitment Related To Vivus Settlement", "terseLabel": "Noncash decrease in API purchase commitment" } } }, "localname": "NoncashDecreaseInApiPurchaseCommitmentRelatedToVivusSettlement", "nsuri": "http://www.petrospharma.com/20230630", "presentation": [ "http://www.petrospharma.com/role/DisclosureMarketingLicensingAndDistributionAgreementsVivusDetails", "http://www.petrospharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ptpi_NoncashDecreaseInOtherCurrentAssetsApiPurchaseCommitment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of Noncash decrease in other current assets: API purchase commitment.", "label": "Noncash Decrease In Other Current Assets: Api Purchase Commitment", "terseLabel": "Noncash decrease in other current assets: API purchase commitment" } } }, "localname": "NoncashDecreaseInOtherCurrentAssetsApiPurchaseCommitment", "nsuri": "http://www.petrospharma.com/20230630", "presentation": [ "http://www.petrospharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ptpi_NoncashIncreaseInPromissoryNoteRelatedToVivusSettlement": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash increase in promissory note related to Vivus settlement.", "label": "Noncash Increase In Promissory Note Related To Vivus Settlement", "terseLabel": "Noncash increase in promissory note related to Vivus settlement" } } }, "localname": "NoncashIncreaseInPromissoryNoteRelatedToVivusSettlement", "nsuri": "http://www.petrospharma.com/20230630", "presentation": [ "http://www.petrospharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ptpi_NoncashIssuanceOfCommonStockToNonEmployee": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash issuance of common stock to non-employee during the period.", "label": "Noncash Issuance of Common Stock to Non-Employee", "terseLabel": "Noncash issuance of common stock to non-employee" } } }, "localname": "NoncashIssuanceOfCommonStockToNonEmployee", "nsuri": "http://www.petrospharma.com/20230630", "presentation": [ "http://www.petrospharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ptpi_NumberOfCustomers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the number of customers.", "label": "Number Of Customers", "terseLabel": "Number of customers" } } }, "localname": "NumberOfCustomers", "nsuri": "http://www.petrospharma.com/20230630", "presentation": [ "http://www.petrospharma.com/role/DisclosureAccountsReceivableNetAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "ptpi_NumberOfEqualMonthlyInstallmentsForRedemptionOfPreferredStock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of equal monthly installments for redemption of preferred stock.", "label": "Number of Equal Monthly Installments for Redemption of Preferred Stock", "terseLabel": "Number of equal monthly installments for redemption of preferred stock" } } }, "localname": "NumberOfEqualMonthlyInstallmentsForRedemptionOfPreferredStock", "nsuri": "http://www.petrospharma.com/20230630", "presentation": [ "http://www.petrospharma.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "integerItemType" }, "ptpi_NumberOfTradingDayConsideredForCalculationOfClosingPriceLimitOfCommonStockForConversion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of trading day considered for calculation of closing price limit of common stock for conversion.", "label": "Number of Trading Day Considered for Calculation of Closing Price Limit of Common Stock for Conversion", "terseLabel": "Number of trading day considered for calculation of closing price limit of common stock for conversion" } } }, "localname": "NumberOfTradingDayConsideredForCalculationOfClosingPriceLimitOfCommonStockForConversion", "nsuri": "http://www.petrospharma.com/20230630", "presentation": [ "http://www.petrospharma.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "durationItemType" }, "ptpi_NumberOfTradingDaysImmediatelyPriorToAmortizationPaymentIsDueConsideredForCalculatingConversionPrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of trading days immediately prior to amortization payment is due considered for calculating conversion price.", "label": "Number of Trading Days Immediately Prior to Amortization Payment is Due Considered for Calculating Conversion Price", "terseLabel": "Number of trading days immediately prior to amortization payment is due considered for calculating conversion price" } } }, "localname": "NumberOfTradingDaysImmediatelyPriorToAmortizationPaymentIsDueConsideredForCalculatingConversionPrice", "nsuri": "http://www.petrospharma.com/20230630", "presentation": [ "http://www.petrospharma.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "durationItemType" }, "ptpi_NumeratorForCalculationOfEarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "No definition.", "label": "Numerator For Calculation Of Earnings Per Share Abstract", "terseLabel": "Numerator" } } }, "localname": "NumeratorForCalculationOfEarningsPerShareAbstract", "nsuri": "http://www.petrospharma.com/20230630", "presentation": [ "http://www.petrospharma.com/role/DisclosureBasicAndDilutedNetIncomeLossPerCommonShareReconciliationOfWeightedAverageNumberOfCommonSharesOutstandingUsedInCalculatingBasicAndDilutedNetLossPerShareDetails" ], "xbrltype": "stringItemType" }, "ptpi_OneCustomersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to one customers.", "label": "One customers" } } }, "localname": "OneCustomersMember", "nsuri": "http://www.petrospharma.com/20230630", "presentation": [ "http://www.petrospharma.com/role/DisclosureAccountsReceivableNetAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "ptpi_OperatingLeaseExpensePerMonth": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of operating lease expense per month.", "label": "Operating Lease Expense Per Month", "terseLabel": "Operating lease expense per month" } } }, "localname": "OperatingLeaseExpensePerMonth", "nsuri": "http://www.petrospharma.com/20230630", "presentation": [ "http://www.petrospharma.com/role/DisclosureOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "ptpi_OperatingLeasesFutureMinimumPaymentsReceivableSubLease": { "auth_ref": [], "calculation": { "http://www.petrospharma.com/role/DisclosureOperatingLeasesFutureMinimumSubleaseIncomeUnderNonCancelableLeasesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Future minimum rental payment for sub-lease in aggregate as of the balance sheet date under operating leases.", "label": "Operating Leases, Future Minimum Payments Receivable, Sub-lease", "totalLabel": "Total" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsReceivableSubLease", "nsuri": "http://www.petrospharma.com/20230630", "presentation": [ "http://www.petrospharma.com/role/DisclosureOperatingLeasesFutureMinimumSubleaseIncomeUnderNonCancelableLeasesDetails" ], "xbrltype": "monetaryItemType" }, "ptpi_OperatingLeasesFutureMinimumPaymentsReceivableSubLeaseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "NA", "label": "Operating Leases, Future Minimum Payments Receivable, Sub-lease [Abstract]", "terseLabel": "Sublease income" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsReceivableSubLeaseAbstract", "nsuri": "http://www.petrospharma.com/20230630", "presentation": [ "http://www.petrospharma.com/role/DisclosureOperatingLeasesFutureMinimumSubleaseIncomeUnderNonCancelableLeasesDetails" ], "xbrltype": "stringItemType" }, "ptpi_OperatingLeasesFutureMinimumPaymentsReceivableSubLeaseInTwoYears": { "auth_ref": [], "calculation": { "http://www.petrospharma.com/role/DisclosureOperatingLeasesFutureMinimumSubleaseIncomeUnderNonCancelableLeasesDetails": { "order": 2.0, "parentTag": "ptpi_OperatingLeasesFutureMinimumPaymentsReceivableSubLease", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Future rental payments receivable for sub-lease within the second year from the balance sheet date under an operating lease.", "label": "Operating Leases, Future Minimum Payments Receivable, Sub-lease, in Two Years", "terseLabel": "2024" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsReceivableSubLeaseInTwoYears", "nsuri": "http://www.petrospharma.com/20230630", "presentation": [ "http://www.petrospharma.com/role/DisclosureOperatingLeasesFutureMinimumSubleaseIncomeUnderNonCancelableLeasesDetails" ], "xbrltype": "monetaryItemType" }, "ptpi_OperatingLeasesFutureMinimumPaymentsReceivableSubLeaseRemainderOfFiscalYear": { "auth_ref": [], "calculation": { "http://www.petrospharma.com/role/DisclosureOperatingLeasesFutureMinimumSubleaseIncomeUnderNonCancelableLeasesDetails": { "order": 1.0, "parentTag": "ptpi_OperatingLeasesFutureMinimumPaymentsReceivableSubLease", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Future rental payments receivable for sub-lease within remainder of fiscal year of the balance sheet date under an operating lease.", "label": "Operating Leases, Future Minimum Payments Receivable, Sub-lease, Remainder of Fiscal Year", "terseLabel": "2023 (remaining 6 months)" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsReceivableSubLeaseRemainderOfFiscalYear", "nsuri": "http://www.petrospharma.com/20230630", "presentation": [ "http://www.petrospharma.com/role/DisclosureOperatingLeasesFutureMinimumSubleaseIncomeUnderNonCancelableLeasesDetails" ], "xbrltype": "monetaryItemType" }, "ptpi_PaymentMadeForPurchaseOrder": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of payment made for purchase order.", "label": "Payment Made For Purchase Order", "terseLabel": "Payment made for purchase order" } } }, "localname": "PaymentMadeForPurchaseOrder", "nsuri": "http://www.petrospharma.com/20230630", "presentation": [ "http://www.petrospharma.com/role/DisclosureMarketingLicensingAndDistributionAgreementsVivusDetails" ], "xbrltype": "monetaryItemType" }, "ptpi_PercentageOfAverageOfThreeLowestClosingPricesOfCommonStockDuringThirtyTradingDayPeriodImmediatelyPriorToAmortizationPaymentIsDue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of the average of three lowest closing prices of common stock during the thirty trading day period immediately prior to amortization payment is due", "label": "Percentage of the Average of Three Lowest Closing Prices of Common Stock During the Thirty Trading Day Period Immediately Prior to Amortization Payment is Due", "terseLabel": "Percentage of the average of three lowest closing prices of common stock during the thirty trading day period immediately prior to amortization payment is due" } } }, "localname": "PercentageOfAverageOfThreeLowestClosingPricesOfCommonStockDuringThirtyTradingDayPeriodImmediatelyPriorToAmortizationPaymentIsDue", "nsuri": "http://www.petrospharma.com/20230630", "presentation": [ "http://www.petrospharma.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "percentItemType" }, "ptpi_PercentageOfCashFeeOnGrossProceedsOfPrivatePlacement": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of cash fee on gross proceeds of private placement.", "label": "Percentage of Cash Fee on Gross Proceeds of Private Placement", "terseLabel": "Cash fee (Percentage)" } } }, "localname": "PercentageOfCashFeeOnGrossProceedsOfPrivatePlacement", "nsuri": "http://www.petrospharma.com/20230630", "presentation": [ "http://www.petrospharma.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "percentItemType" }, "ptpi_PercentageOfConversionSharesAndWarrantSharesRequiredToFileForResale": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of conversion shares and warrant shares required to file for resale.", "label": "Percentage of Conversion Shares and Warrant Shares Required to File for Resale", "terseLabel": "Percentage of conversion shares and warrant shares required to file for resale" } } }, "localname": "PercentageOfConversionSharesAndWarrantSharesRequiredToFileForResale", "nsuri": "http://www.petrospharma.com/20230630", "presentation": [ "http://www.petrospharma.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "percentItemType" }, "ptpi_PercentageOfMinimumPriceAsDefinedInNasdaqStockMarketRule": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of minimum price as defined in Nasdaq Stock Market Rule on the date of the Nasdaq Stockholder Approval.", "label": "Percentage of Minimum Price as Defined in Nasdaq Stock Market Rule", "terseLabel": "Percentage of minimum price" } } }, "localname": "PercentageOfMinimumPriceAsDefinedInNasdaqStockMarketRule", "nsuri": "http://www.petrospharma.com/20230630", "presentation": [ "http://www.petrospharma.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "percentItemType" }, "ptpi_PercentageOfRedemptionsPayableInCashOnInstallmentRedemptionAmount": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of redemptions payable in cash on installment redemption amount.", "label": "Percentage of Redemptions Payable in Cash on Installment Redemption Amount", "terseLabel": "Percentage of redemptions payable in cash on installment redemption amount" } } }, "localname": "PercentageOfRedemptionsPayableInCashOnInstallmentRedemptionAmount", "nsuri": "http://www.petrospharma.com/20230630", "presentation": [ "http://www.petrospharma.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "percentItemType" }, "ptpi_PercentageOfStendraTabletsReleased": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the percentage of stendra tablets released.", "label": "Percentage Of Stendra Tablets Released", "terseLabel": "Percentage of stendra tablets released" } } }, "localname": "PercentageOfStendraTabletsReleased", "nsuri": "http://www.petrospharma.com/20230630", "presentation": [ "http://www.petrospharma.com/role/DisclosureMarketingLicensingAndDistributionAgreementsVivusDetails" ], "xbrltype": "pureItemType" }, "ptpi_PreferredStockDividendsAccruedDividendPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred stock, dividend accrued rate per annum.", "label": "Preferred Stock Dividends Accrued, Dividend Percentage", "terseLabel": "Preferred stock, dividend accrued rate per annum" } } }, "localname": "PreferredStockDividendsAccruedDividendPercentage", "nsuri": "http://www.petrospharma.com/20230630", "presentation": [ "http://www.petrospharma.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "percentItemType" }, "ptpi_PreferredStockStatedValuePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share price of state value of preferred stock.", "label": "Preferred Stock Stated Value Per Share", "terseLabel": "Preferred stock, stated value" } } }, "localname": "PreferredStockStatedValuePerShare", "nsuri": "http://www.petrospharma.com/20230630", "presentation": [ "http://www.petrospharma.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "perShareItemType" }, "ptpi_PrepaidCouponFeeCurrent": { "auth_ref": [], "calculation": { "http://www.petrospharma.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails": { "order": 3.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of coupon fee paid in advance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Coupon Fee Current", "terseLabel": "Prepaid coupon fees" } } }, "localname": "PrepaidCouponFeeCurrent", "nsuri": "http://www.petrospharma.com/20230630", "presentation": [ "http://www.petrospharma.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "ptpi_PrepaidPurchaseCommitmentAssetCurrent": { "auth_ref": [], "calculation": { "http://www.petrospharma.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails": { "order": 5.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for API purchase commitments that provides economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Purchase Commitment Asset Current", "terseLabel": "API purchase commitment asset", "verboseLabel": "API purchase commitment asset" } } }, "localname": "PrepaidPurchaseCommitmentAssetCurrent", "nsuri": "http://www.petrospharma.com/20230630", "presentation": [ "http://www.petrospharma.com/role/DisclosureMarketingLicensingAndDistributionAgreementsVivusDetails", "http://www.petrospharma.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "ptpi_PrepaymentAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of prepayment amount.", "label": "Prepayment Amount", "terseLabel": "Prepayment amount" } } }, "localname": "PrepaymentAmount", "nsuri": "http://www.petrospharma.com/20230630", "presentation": [ "http://www.petrospharma.com/role/DisclosureMarketingLicensingAndDistributionAgreementsVivusDetails" ], "xbrltype": "monetaryItemType" }, "ptpi_PrescriptionMedicationSalesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Prescription Medication Sales.", "label": "Prescription Medications" } } }, "localname": "PrescriptionMedicationSalesMember", "nsuri": "http://www.petrospharma.com/20230630", "presentation": [ "http://www.petrospharma.com/role/DisclosureSegmentInformationDetails", "http://www.petrospharma.com/role/DisclosureSegmentInformationSegmentAssetsDetails", "http://www.petrospharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "ptpi_PromissoryNoteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for promissory note.", "label": "Promissory Note", "terseLabel": "Promissory Note" } } }, "localname": "PromissoryNoteMember", "nsuri": "http://www.petrospharma.com/20230630", "presentation": [ "http://www.petrospharma.com/role/DisclosureMarketingLicensingAndDistributionAgreementsVivusDetails" ], "xbrltype": "domainItemType" }, "ptpi_PtvProductMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to PTV product .", "label": "PTV product" } } }, "localname": "PtvProductMember", "nsuri": "http://www.petrospharma.com/20230630", "presentation": [ "http://www.petrospharma.com/role/DisclosureIntangibleAssetsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "ptpi_RegistrationRightsAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to registration rights agreement.", "label": "Registration rights agreement" } } }, "localname": "RegistrationRightsAgreementMember", "nsuri": "http://www.petrospharma.com/20230630", "presentation": [ "http://www.petrospharma.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "ptpi_RestrictedStockUnitsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "RSUs", "terseLabel": "RSUs" } } }, "localname": "RestrictedStockUnitsMember", "nsuri": "http://www.petrospharma.com/20230630", "presentation": [ "http://www.petrospharma.com/role/DisclosureBasicAndDilutedNetIncomeLossPerCommonSharePotentiallyDilutiveSecuritiesConvertibleIntoCommonSharesThatWereExcludedFromCalculationOfDilutedNetIncomeLossPerShareDetails" ], "xbrltype": "domainItemType" }, "ptpi_RisksAndUncertaintiesPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for Risks and Uncertainties.", "label": "Risks and Uncertainties [Policy Text Block]", "terseLabel": "Risks and Uncertainties" } } }, "localname": "RisksAndUncertaintiesPolicyTextBlock", "nsuri": "http://www.petrospharma.com/20230630", "presentation": [ "http://www.petrospharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ptpi_RoyaltyReceivable": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the amount of royalty receivable as of balance sheet date.", "label": "Royalty Receivable", "terseLabel": "Royalty receivable" } } }, "localname": "RoyaltyReceivable", "nsuri": "http://www.petrospharma.com/20230630", "presentation": [ "http://www.petrospharma.com/role/DisclosureMarketingLicensingAndDistributionAgreementsVivusDetails" ], "xbrltype": "monetaryItemType" }, "ptpi_ScenarioFiveMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the scenario of milestone payment to be paid once $250 million in sales has been reached.", "label": "Milestone payment to be paid once $250 million in sales has been reached", "terseLabel": "Milestone payment to be paid once $250 million in sales has been reached" } } }, "localname": "ScenarioFiveMember", "nsuri": "http://www.petrospharma.com/20230630", "presentation": [ "http://www.petrospharma.com/role/DisclosureMarketingLicensingAndDistributionAgreementsVivusDetails" ], "xbrltype": "domainItemType" }, "ptpi_ScenarioFourMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the scenario of royalty following the fourth and fifth years following the end of the Royalty Period.", "label": "Royalty following the fourth and fifth years following the end of the Royalty Period", "terseLabel": "Royalty following the fourth and fifth years following the end of the Royalty Period" } } }, "localname": "ScenarioFourMember", "nsuri": "http://www.petrospharma.com/20230630", "presentation": [ "http://www.petrospharma.com/role/DisclosureMarketingLicensingAndDistributionAgreementsVivusDetails" ], "xbrltype": "domainItemType" }, "ptpi_ScenarioOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the scenario of royalty on the first $500 million of net sales.", "label": "Royalty on the first $500 million of net sales", "terseLabel": "Royalty on the first $500 million of net sales" } } }, "localname": "ScenarioOneMember", "nsuri": "http://www.petrospharma.com/20230630", "presentation": [ "http://www.petrospharma.com/role/DisclosureMarketingLicensingAndDistributionAgreementsVivusDetails" ], "xbrltype": "domainItemType" }, "ptpi_ScenarioSixMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the scenario of milestone payment to be paid after $250 million in sales has been reached.", "label": "Milestone payment to be paid after $250 million in sales has been reached", "terseLabel": "Milestone payment to be paid after $250 million in sales has been reached" } } }, "localname": "ScenarioSixMember", "nsuri": "http://www.petrospharma.com/20230630", "presentation": [ "http://www.petrospharma.com/role/DisclosureMarketingLicensingAndDistributionAgreementsVivusDetails" ], "xbrltype": "domainItemType" }, "ptpi_ScenarioThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the scenario of royalty during the first, second, and third years following the expiration of the Royalty Period.", "label": "Royalty during the first, second, and third years following the expiration of the Royalty Period", "terseLabel": "Royalty during the first, second, and third years following the expiration of the Royalty Period" } } }, "localname": "ScenarioThreeMember", "nsuri": "http://www.petrospharma.com/20230630", "presentation": [ "http://www.petrospharma.com/role/DisclosureMarketingLicensingAndDistributionAgreementsVivusDetails" ], "xbrltype": "domainItemType" }, "ptpi_ScenarioTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the scenario of royalty on net sales after $500 million.", "label": "Royalty on net sales after $500 million", "terseLabel": "Royalty on net sales after $500 million" } } }, "localname": "ScenarioTwoMember", "nsuri": "http://www.petrospharma.com/20230630", "presentation": [ "http://www.petrospharma.com/role/DisclosureMarketingLicensingAndDistributionAgreementsVivusDetails" ], "xbrltype": "domainItemType" }, "ptpi_ScheduleOfFutureMinimumRentalPaymentsReceivableForSubLeasesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of future minimum receivables for sub-lease required in the aggregate and for each of the five succeeding fiscal years for sub leases having initial or remaining noncancelable lease terms in excess of one year.", "label": "Schedule of Future Minimum Rental Payments Receivable for Sub Leases [Table Text Block]", "terseLabel": "Schedule of future minimum sublease income under non-cancelable leases" } } }, "localname": "ScheduleOfFutureMinimumRentalPaymentsReceivableForSubLeasesTableTextBlock", "nsuri": "http://www.petrospharma.com/20230630", "presentation": [ "http://www.petrospharma.com/role/DisclosureOperatingLeasesTables" ], "xbrltype": "textBlockItemType" }, "ptpi_ScheduleOfPrepaidExpenseAndOtherAssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "No definition.", "label": "Prepaid Expenses and Other Current Assets." } } }, "localname": "ScheduleOfPrepaidExpenseAndOtherAssetsCurrentAbstract", "nsuri": "http://www.petrospharma.com/20230630", "xbrltype": "stringItemType" }, "ptpi_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amounts paid in advance for prepaid costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet.", "label": "Schedule Of Prepaid Expenses And Other Current Assets Table Text Block", "terseLabel": "Schedule of prepaid expenses and other current assets" } } }, "localname": "ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock", "nsuri": "http://www.petrospharma.com/20230630", "presentation": [ "http://www.petrospharma.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables" ], "xbrltype": "textBlockItemType" }, "ptpi_ScheduleOfWarrantsAndRightsByExpirationDateTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The tabular disclosure of warrants by expiration date.", "label": "Schedule of Warrants And Rights by Expiration Date [Table Text Block]", "verboseLabel": "Schedule of warrants by expiration date" } } }, "localname": "ScheduleOfWarrantsAndRightsByExpirationDateTableTextBlock", "nsuri": "http://www.petrospharma.com/20230630", "presentation": [ "http://www.petrospharma.com/role/DisclosureCommonStockWarrantsTables" ], "xbrltype": "textBlockItemType" }, "ptpi_SecuritiesPurchaseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to securities purchase agreement.", "label": "Securities purchase agreement", "terseLabel": "Purchase Agreement" } } }, "localname": "SecuritiesPurchaseAgreementMember", "nsuri": "http://www.petrospharma.com/20230630", "presentation": [ "http://www.petrospharma.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "ptpi_SecurityDepositForSubLeaseReceived": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of security deposit received for sublease from sub lessor.", "label": "Security Deposit For Sub Lease Received", "terseLabel": "Security deposit received for sublease" } } }, "localname": "SecurityDepositForSubLeaseReceived", "nsuri": "http://www.petrospharma.com/20230630", "presentation": [ "http://www.petrospharma.com/role/DisclosureOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "ptpi_SeriesConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to Series A Convertible Preferred Stock.", "label": "Series A Convertible Preferred Stock [Member]", "terseLabel": "Series A Preferred Stock" } } }, "localname": "SeriesConvertiblePreferredStockMember", "nsuri": "http://www.petrospharma.com/20230630", "presentation": [ "http://www.petrospharma.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "ptpi_SettlementAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for Settlement Agreement.", "label": "Settlement Agreement", "terseLabel": "Settlement Agreement" } } }, "localname": "SettlementAgreementMember", "nsuri": "http://www.petrospharma.com/20230630", "presentation": [ "http://www.petrospharma.com/role/DisclosureMarketingLicensingAndDistributionAgreementsVivusDetails" ], "xbrltype": "domainItemType" }, "ptpi_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfDirectorsToWhomOptionIsGranted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the number of directors to whom option is granted in share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Directors to Whom Option is Granted", "verboseLabel": "Number of directors to whom option is granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfDirectorsToWhomOptionIsGranted", "nsuri": "http://www.petrospharma.com/20230630", "presentation": [ "http://www.petrospharma.com/role/DisclosureStockOptionsAndRestrictedStockUnitsrsuSAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "ptpi_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedIntrinsicValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options granted.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Granted, Intrinsic Value", "terseLabel": "Options granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedIntrinsicValue", "nsuri": "http://www.petrospharma.com/20230630", "presentation": [ "http://www.petrospharma.com/role/DisclosureStockOptionsAndRestrictedStockUnitsrsuSSummaryOfStockOptionsDetails" ], "xbrltype": "monetaryItemType" }, "ptpi_StendraProductMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Stendra product.", "label": "Stendra product" } } }, "localname": "StendraProductMember", "nsuri": "http://www.petrospharma.com/20230630", "presentation": [ "http://www.petrospharma.com/role/DisclosureIntangibleAssetsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "ptpi_StockIssuedDuringPeriodSharesRestrictedStockAwardVested": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares related to Restricted Stock Award vested during the period.", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Vested", "terseLabel": "Shares issued for vested RSU's (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardVested", "nsuri": "http://www.petrospharma.com/20230630", "presentation": [ "http://www.petrospharma.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "sharesItemType" }, "ptpi_StockIssuedDuringPeriodValueRestrictedStockAwardVested": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate value of stock related to Restricted Stock Awards vested during the period.", "label": "Stock Issued During Period, Value, Restricted Stock Award, Vested", "terseLabel": "Shares issued for vested RSU's" } } }, "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardVested", "nsuri": "http://www.petrospharma.com/20230630", "presentation": [ "http://www.petrospharma.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "ptpi_SummaryOfPrepaidExpensesAndOtherCurrentAssetsTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure information about prepaid expenses and other current assets", "label": "Summary of Prepaid Expenses and Other Current Assets Text Block", "terseLabel": "Prepaid Expenses and Other Current Assets" } } }, "localname": "SummaryOfPrepaidExpensesAndOtherCurrentAssetsTextBlock", "nsuri": "http://www.petrospharma.com/20230630", "presentation": [ "http://www.petrospharma.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets" ], "xbrltype": "textBlockItemType" }, "ptpi_TaniaKingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Tania King.", "label": "Tania King" } } }, "localname": "TaniaKingMember", "nsuri": "http://www.petrospharma.com/20230630", "presentation": [ "http://www.petrospharma.com/role/DisclosureStockOptionsAndRestrictedStockUnitsrsuSAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "ptpi_ThreeCustomersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to three customers.", "label": "Three customers" } } }, "localname": "ThreeCustomersMember", "nsuri": "http://www.petrospharma.com/20230630", "presentation": [ "http://www.petrospharma.com/role/DisclosureAccountsReceivableNetAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "ptpi_ThresholdNumberOfCalendarDaysForFilingResaleAfterEffectiveDateOfRegistrationRightsAgreement": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Threshold number of calendar days for filing resale after the effective date of registration rights agreement.", "label": "Threshold Number of Calendar Days for Filing Resale After the Effective Date of Registration Rights Agreement", "terseLabel": "Threshold number of calendar days for filing resale" } } }, "localname": "ThresholdNumberOfCalendarDaysForFilingResaleAfterEffectiveDateOfRegistrationRightsAgreement", "nsuri": "http://www.petrospharma.com/20230630", "presentation": [ "http://www.petrospharma.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "durationItemType" }, "ptpi_TimmMedicalProductMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Timm Medical product.", "label": "Timm Medical product" } } }, "localname": "TimmMedicalProductMember", "nsuri": "http://www.petrospharma.com/20230630", "presentation": [ "http://www.petrospharma.com/role/DisclosureIntangibleAssetsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "ptpi_TwoCustomersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to two customers.", "label": "Two customers" } } }, "localname": "TwoCustomersMember", "nsuri": "http://www.petrospharma.com/20230630", "presentation": [ "http://www.petrospharma.com/role/DisclosureAccountsReceivableNetAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "ptpi_VivusIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Vivus, Inc.", "label": "Vivus, Inc", "terseLabel": "Vivus, Inc" } } }, "localname": "VivusIncMember", "nsuri": "http://www.petrospharma.com/20230630", "presentation": [ "http://www.petrospharma.com/role/DisclosureMarketingLicensingAndDistributionAgreementsVivusDetails" ], "xbrltype": "domainItemType" }, "ptpi_WarrantsAndRightsNoteDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure on warrants and rights.", "label": "Warrants And Rights Note Disclosure [Text Block]", "verboseLabel": "Common Stock Warrants" } } }, "localname": "WarrantsAndRightsNoteDisclosureTextBlock", "nsuri": "http://www.petrospharma.com/20230630", "presentation": [ "http://www.petrospharma.com/role/DisclosureCommonStockWarrants" ], "xbrltype": "textBlockItemType" }, "ptpi_WorkingCapital": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of net current assets (current liabilities).", "label": "Working Capital", "terseLabel": "Working capital" } } }, "localname": "WorkingCapital", "nsuri": "http://www.petrospharma.com/20230630", "presentation": [ "http://www.petrospharma.com/role/DisclosureNatureOfOperationsBasisOfPresentationLiquidityAndGoingConcernAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "srt_ConsolidationItemsAxis": { "auth_ref": [ "r160", "r197", "r214", "r215", "r216", "r217", "r218", "r220", "r224", "r265", "r266", "r267", "r268", "r270", "r271", "r273", "r275", "r276", "r654", "r655" ], "lang": { "en-us": { "role": { "label": "Consolidation Items [Axis]" } } }, "localname": "ConsolidationItemsAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureSegmentInformationDetails" ], "xbrltype": "stringItemType" }, "srt_ConsolidationItemsDomain": { "auth_ref": [ "r160", "r197", "r214", "r215", "r216", "r217", "r218", "r220", "r224", "r265", "r266", "r267", "r268", "r270", "r271", "r273", "r275", "r276", "r654", "r655" ], "lang": { "en-us": { "role": { "label": "Consolidation Items [Domain]" } } }, "localname": "ConsolidationItemsDomain", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureSegmentInformationDetails" ], "xbrltype": "domainItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r158", "r159", "r282", "r310", "r409", "r570", "r572" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]", "terseLabel": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureMarketingLicensingAndDistributionAgreementsVivusDetails", "http://www.petrospharma.com/role/DisclosureStockOptionsAndRestrictedStockUnitsrsuSAdditionalInformationDetails", "http://www.petrospharma.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r230", "r588", "r657", "r678", "r679" ], "lang": { "en-us": { "role": { "label": "Customer [Axis]" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureAccountsReceivableNetAdditionalInformationDetails", "http://www.petrospharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r261", "r262", "r263", "r264", "r328", "r414", "r443", "r475", "r476", "r528", "r531", "r535", "r536", "r538", "r561", "r562", "r577", "r585", "r593", "r600", "r656", "r669", "r670", "r671", "r672", "r673", "r674" ], "lang": { "en-us": { "role": { "label": "Maximum", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureOperatingLeasesDetails", "http://www.petrospharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r261", "r262", "r263", "r264", "r328", "r414", "r443", "r475", "r476", "r528", "r531", "r535", "r536", "r538", "r561", "r562", "r577", "r585", "r593", "r600", "r656", "r669", "r670", "r671", "r672", "r673", "r674" ], "lang": { "en-us": { "role": { "label": "Minimum", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureOperatingLeasesDetails", "http://www.petrospharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [ "r230", "r588", "r657", "r678", "r679" ], "lang": { "en-us": { "role": { "label": "Customer [Domain]" } } }, "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureAccountsReceivableNetAdditionalInformationDetails", "http://www.petrospharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r261", "r262", "r263", "r264", "r327", "r328", "r357", "r358", "r359", "r413", "r414", "r443", "r475", "r476", "r528", "r531", "r535", "r536", "r538", "r561", "r562", "r577", "r585", "r593", "r600", "r603", "r651", "r656", "r670", "r671", "r672", "r673", "r674" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureOperatingLeasesDetails", "http://www.petrospharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r261", "r262", "r263", "r264", "r327", "r328", "r357", "r358", "r359", "r413", "r414", "r443", "r475", "r476", "r528", "r531", "r535", "r536", "r538", "r561", "r562", "r577", "r585", "r593", "r600", "r603", "r651", "r656", "r670", "r671", "r672", "r673", "r674" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureOperatingLeasesDetails", "http://www.petrospharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [ "r158", "r159", "r282", "r310", "r409", "r571", "r572" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]", "terseLabel": "Counterparty Name [Domain]" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureMarketingLicensingAndDistributionAgreementsVivusDetails", "http://www.petrospharma.com/role/DisclosureStockOptionsAndRestrictedStockUnitsrsuSAdditionalInformationDetails", "http://www.petrospharma.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioUnspecifiedDomain": { "auth_ref": [ "r174", "r329", "r621", "r642" ], "lang": { "en-us": { "role": { "label": "Scenario [Domain]" } } }, "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureMarketingLicensingAndDistributionAgreementsVivusDetails" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r228", "r229", "r472", "r473", "r474", "r530", "r533", "r537", "r542", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r564", "r587", "r603", "r657", "r678" ], "lang": { "en-us": { "role": { "label": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureSegmentInformationNetSalesByGeographicRegionDetails" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r228", "r229", "r472", "r473", "r474", "r530", "r533", "r537", "r542", "r548", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r564", "r587", "r603", "r657", "r678" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureSegmentInformationNetSalesByGeographicRegionDetails" ], "xbrltype": "stringItemType" }, "srt_StatementScenarioAxis": { "auth_ref": [ "r174", "r329", "r621", "r622", "r642" ], "lang": { "en-us": { "role": { "label": "Scenario [Axis]" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureMarketingLicensingAndDistributionAgreementsVivusDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Summary of Significant Accounting Policies" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_AccountsNotesLoansAndFinancingReceivableGrossAllowanceAndNetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounts Receivable, net" } } }, "localname": "AccountsNotesLoansAndFinancingReceivableGrossAllowanceAndNetAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r15", "r599" ], "calculation": { "http://www.petrospharma.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "verboseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableGross": { "auth_ref": [ "r137", "r231", "r677" ], "calculation": { "http://www.petrospharma.com/role/DisclosureAccountsReceivableNetDetails": { "order": 2.0, "parentTag": "us-gaap_AccountsReceivableNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.", "label": "Accounts Receivable, before Allowance for Credit Loss", "terseLabel": "Gross accounts receivables" } } }, "localname": "AccountsReceivableGross", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureAccountsReceivableNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableMember": { "auth_ref": [ "r550" ], "lang": { "en-us": { "role": { "documentation": "Due from customers or clients for goods or services that have been delivered or sold.", "label": "Receivables from customers", "terseLabel": "Account receivables" } } }, "localname": "AccountsReceivableMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureAccountsReceivableNetAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsReceivableNet": { "auth_ref": [ "r493", "r549", "r604", "r677" ], "calculation": { "http://www.petrospharma.com/role/DisclosureAccountsReceivableNetDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.", "label": "Accounts Receivable, after Allowance for Credit Loss", "totalLabel": "Total accounts receivable, net" } } }, "localname": "AccountsReceivableNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureAccountsReceivableNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r231", "r232" ], "calculation": { "http://www.petrospharma.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Accounts receivable, net" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedBonusesCurrent": { "auth_ref": [ "r18" ], "calculation": { "http://www.petrospharma.com/role/DisclosureAccruedExpensesDetails": { "order": 4.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Bonuses, Current", "terseLabel": "Accrued bonuses" } } }, "localname": "AccruedBonusesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedExchangeFeeRebateCurrentAndNoncurrent": { "auth_ref": [ "r64" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for rebates of an exchange fee some mutual funds impose on shareholders if they exchange (transfer) to another fund within the same fund group.", "label": "Accrued Exchange Fee Rebate", "terseLabel": "Accrued contract rebates" } } }, "localname": "AccruedExchangeFeeRebateCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r18" ], "calculation": { "http://www.petrospharma.com/role/DisclosureAccruedExpensesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.petrospharma.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "terseLabel": "Accrued expenses", "totalLabel": "Total accrued expenses" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureAccruedExpensesDetails", "http://www.petrospharma.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accrued Expenses" } } }, "localname": "AccruedLiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_AccruedProfessionalFeesCurrent": { "auth_ref": [ "r18" ], "calculation": { "http://www.petrospharma.com/role/DisclosureAccruedExpensesDetails": { "order": 3.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Professional Fees, Current", "terseLabel": "Accrued professional fees" } } }, "localname": "AccruedProfessionalFeesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r73", "r599", "r681" ], "calculation": { "http://www.petrospharma.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r364", "r365", "r366", "r459", "r639", "r640", "r641", "r661", "r682" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r54", "r55", "r332" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Stock-based compensation expense" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "verboseLabel": "Adjustments to reconcile net income (loss) to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivable": { "auth_ref": [ "r138", "r233", "r237", "r238", "r240", "r677" ], "calculation": { "http://www.petrospharma.com/role/DisclosureAccountsReceivableNetDetails": { "order": 1.0, "parentTag": "us-gaap_AccountsReceivableNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable.", "label": "Accounts Receivable, Allowance for Credit Loss", "negatedLabel": "Allowance for doubtful accounts" } } }, "localname": "AllowanceForDoubtfulAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureAccountsReceivableNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r4", "r44", "r48" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of Intangible Assets", "negatedLabel": "Amortization expense" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r184" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Total" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureBasicAndDilutedNetIncomeLossPerCommonSharePotentiallyDilutiveSecuritiesConvertibleIntoCommonSharesThatWereExcludedFromCalculationOfDilutedNetIncomeLossPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r26" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureBasicAndDilutedNetIncomeLossPerCommonSharePotentiallyDilutiveSecuritiesConvertibleIntoCommonSharesThatWereExcludedFromCalculationOfDilutedNetIncomeLossPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "terseLabel": "Antidilutive securities convertible into common shares" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureBasicAndDilutedNetIncomeLossPerCommonSharePotentiallyDilutiveSecuritiesConvertibleIntoCommonSharesThatWereExcludedFromCalculationOfDilutedNetIncomeLossPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r26" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureBasicAndDilutedNetIncomeLossPerCommonSharePotentiallyDilutiveSecuritiesConvertibleIntoCommonSharesThatWereExcludedFromCalculationOfDilutedNetIncomeLossPerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [ "r370" ], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]" } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureMarketingLicensingAndDistributionAgreementsVivusDetails", "http://www.petrospharma.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r106", "r131", "r157", "r195", "r216", "r222", "r234", "r265", "r266", "r268", "r269", "r270", "r272", "r274", "r276", "r277", "r372", "r376", "r387", "r422", "r498", "r599", "r612", "r654", "r655", "r667" ], "calculation": { "http://www.petrospharma.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets", "verboseLabel": "Total segment assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureSegmentInformationSegmentAssetsDetails", "http://www.petrospharma.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsAndLiabilitiesLesseeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental balance sheet information related to leases", "terseLabel": "Supplemental balance sheet information related to leases" } } }, "localname": "AssetsAndLiabilitiesLesseeAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureOperatingLeasesSupplementalBalanceSheetInformationRelatedToLeasesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r127", "r141", "r157", "r234", "r265", "r266", "r268", "r269", "r270", "r272", "r274", "r276", "r277", "r372", "r376", "r387", "r599", "r654", "r655", "r667" ], "calculation": { "http://www.petrospharma.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureStockOptionsAndRestrictedStockUnitsrsuSAdditionalInformationDetails", "http://www.petrospharma.com/role/DisclosureStockOptionsAndRestrictedStockUnitsrsuSSummaryOfStockOptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureMarketingLicensingAndDistributionAgreementsVivusDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r56", "r57" ], "lang": { "en-us": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureMarketingLicensingAndDistributionAgreementsVivusDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Cash": { "auth_ref": [ "r113", "r423", "r470", "r492", "r599", "r612", "r627" ], "calculation": { "http://www.petrospharma.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash", "terseLabel": "Cash" } } }, "localname": "Cash", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r25", "r129", "r565" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "verboseLabel": "Cash" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureNatureOfOperationsBasisOfPresentationLiquidityAndGoingConcernAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r25", "r90", "r154" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash, end of period", "periodStartLabel": "Cash, beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r1", "r90" ], "calculation": { "http://www.petrospharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net decrease in cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r123", "r134", "r135", "r136", "r157", "r178", "r179", "r181", "r183", "r189", "r190", "r234", "r265", "r268", "r269", "r270", "r276", "r277", "r307", "r308", "r311", "r312", "r313", "r387", "r453", "r454", "r455", "r456", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r471", "r484", "r507", "r525", "r543", "r544", "r545", "r546", "r547", "r620", "r635", "r643" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightAxis": { "auth_ref": [ "r51" ], "lang": { "en-us": { "role": { "documentation": "Information by type of warrant or right issued.", "label": "Class of Warrant or Right [Axis]" } } }, "localname": "ClassOfWarrantOrRightAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureCommonStockWarrantsCompanySWarrantsByExpirationDateDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.", "label": "Class of Warrant or Right [Domain]" } } }, "localname": "ClassOfWarrantOrRightDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureCommonStockWarrantsCompanySWarrantsByExpirationDateDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r314" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "terseLabel": "Exercise price of warrants", "verboseLabel": "Exercise Price" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureCommonStockWarrantsCompanySWarrantsByExpirationDateDetails", "http://www.petrospharma.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ClassOfWarrantOrRightLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Warrant or Right [Line Items]", "terseLabel": "Class of Warrant or Right" } } }, "localname": "ClassOfWarrantOrRightLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureCommonStockWarrantsCompanySWarrantsByExpirationDateDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "auth_ref": [ "r314" ], "lang": { "en-us": { "role": { "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.", "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights", "terseLabel": "Warrants to purchase shares of common stock" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrants or rights outstanding.", "label": "Class of Warrant or Right, Outstanding", "terseLabel": "Number of Warrants" } } }, "localname": "ClassOfWarrantOrRightOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureCommonStockWarrantsCompanySWarrantsByExpirationDateDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ClassOfWarrantOrRightTable": { "auth_ref": [ "r51" ], "lang": { "en-us": { "role": { "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.", "label": "Class of Warrant or Right [Table]" } } }, "localname": "ClassOfWarrantOrRightTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureCommonStockWarrantsCompanySWarrantsByExpirationDateDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CollaborativeArrangementDisclosureTextBlock": { "auth_ref": [ "r114", "r116", "r122" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.", "label": "Collaborative Arrangement Disclosure [Text Block]", "terseLabel": "Marketing, Licensing and Distribution Agreements" } } }, "localname": "CollaborativeArrangementDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureMarketingLicensingAndDistributionAgreements" ], "xbrltype": "textBlockItemType" }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "auth_ref": [ "r370" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]", "verboseLabel": "Marketing, Licensing and Distribution Agreements" } } }, "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureMarketingLicensingAndDistributionAgreementsVivusDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r98", "r259", "r260", "r551", "r652" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureCommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r601", "r602", "r603", "r605", "r606", "r607", "r608", "r639", "r640", "r661", "r680", "r682" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r72" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureSubsequentEventsDetails", "http://www.petrospharma.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r72", "r484" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r72" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r8", "r72", "r484", "r504", "r682", "r683" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r72", "r424", "r599" ], "calculation": { "http://www.petrospharma.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock (par value $0.0001 per share, 150,000,000 shares authorized, 2,119,620 and 2,079,387 shares issued and outstanding as of June 30, 2023 and December 31, 2022, respectively)" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r29", "r31", "r59", "r60", "r230", "r550" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.", "label": "Concentration Risk Benchmark [Domain]" } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureAccountsReceivableNetAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r29", "r31", "r59", "r60", "r230", "r449", "r550" ], "lang": { "en-us": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureAccountsReceivableNetAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r29", "r31", "r59", "r60", "r230", "r550", "r625" ], "lang": { "en-us": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk Type [Axis]" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureAccountsReceivableNetAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r66", "r118" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "verboseLabel": "Concentration of Credit Risk" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskLineItems": { "auth_ref": [ "r550" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Concentration Risk [Line Items]", "terseLabel": "Accounts Receivable, net" } } }, "localname": "ConcentrationRiskLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureAccountsReceivableNetAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r29", "r31", "r59", "r60", "r230" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "Concentration Risk, Percentage", "terseLabel": "Concentration risk percentage" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureAccountsReceivableNetAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskTable": { "auth_ref": [ "r28", "r29", "r31", "r32", "r59", "r105", "r550" ], "lang": { "en-us": { "role": { "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.", "label": "Concentration Risk [Table]" } } }, "localname": "ConcentrationRiskTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureAccountsReceivableNetAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r29", "r31", "r59", "r60", "r230", "r550" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.", "label": "Concentration Risk Type [Domain]" } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureAccountsReceivableNetAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ContractWithCustomerRefundLiabilityCurrent": { "auth_ref": [ "r658" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability for consideration received or receivable from customer which is not included in transaction price, when consideration is expected to be refunded to customer, classified as current.", "label": "Contract with Customer, Refund Liability, Current", "terseLabel": "Reserves for product returns" } } }, "localname": "ContractWithCustomerRefundLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CorporateNonSegmentMember": { "auth_ref": [ "r11", "r215", "r216", "r217", "r218", "r224", "r646" ], "lang": { "en-us": { "role": { "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment.", "label": "Corporate" } } }, "localname": "CorporateNonSegmentMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureSegmentInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r86", "r416" ], "calculation": { "http://www.petrospharma.com/role/StatementCondensedConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of Goods and Services Sold", "terseLabel": "Cost of goods sold" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureSegmentInformationDetails", "http://www.petrospharma.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_CreditConcentrationRiskMember": { "auth_ref": [ "r105" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that a specified receivable or amount at risk from a counterparty under a contractual arrangement is to a specified benchmark, such as total receivables, net revenues, pretax results. Risk is the materially adverse effects of loss attributable to (a) the failure to collect a significant receivable from a major customer or group of homogeneous accounts, or (b) a failure by a counterparty to perform under terms of a contractual arrangement.", "label": "Credit concentration risk" } } }, "localname": "CreditConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureAccountsReceivableNetAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CustomerConcentrationRiskMember": { "auth_ref": [ "r30", "r230" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.", "label": "Customer concentration risk" } } }, "localname": "CustomerConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureAccountsReceivableNetAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r99", "r156", "r278", "r284", "r285", "r286", "r287", "r288", "r289", "r294", "r301", "r302", "r304" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "terseLabel": "Debt" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureDebt" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r13", "r69", "r70", "r107", "r108", "r160", "r279", "r280", "r281", "r282", "r283", "r285", "r290", "r291", "r292", "r293", "r295", "r296", "r297", "r298", "r299", "r300", "r395", "r580", "r581", "r582", "r583", "r584", "r636" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureDebtFutureMinimumPrincipalPaymentsDetails", "http://www.petrospharma.com/role/DisclosureDebtPromissoryNoteDetails", "http://www.petrospharma.com/role/DisclosureMarketingLicensingAndDistributionAgreementsVivusDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r62", "r63", "r279", "r395", "r581", "r582" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument, Face Amount", "verboseLabel": "Principal amount of notes payable" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureDebtPromissoryNoteDetails", "http://www.petrospharma.com/role/DisclosureMarketingLicensingAndDistributionAgreementsVivusDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r20", "r280" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage", "verboseLabel": "Interest rate (in percent)" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureDebtPromissoryNoteDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [ "r160", "r279", "r280", "r281", "r282", "r283", "r285", "r290", "r291", "r292", "r293", "r295", "r296", "r297", "r298", "r299", "r300", "r303", "r395", "r580", "r581", "r582", "r583", "r584", "r636" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument", "terseLabel": "Debt Instrument" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureDebtFutureMinimumPrincipalPaymentsDetails", "http://www.petrospharma.com/role/DisclosureDebtPromissoryNoteDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r21", "r160", "r279", "r280", "r281", "r282", "r283", "r285", "r290", "r291", "r292", "r293", "r295", "r296", "r297", "r298", "r299", "r300", "r395", "r580", "r581", "r582", "r583", "r584", "r636" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureDebtFutureMinimumPrincipalPaymentsDetails", "http://www.petrospharma.com/role/DisclosureDebtPromissoryNoteDetails", "http://www.petrospharma.com/role/DisclosureMarketingLicensingAndDistributionAgreementsVivusDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r21", "r49", "r50", "r61", "r62", "r63", "r65", "r100", "r101", "r160", "r279", "r280", "r281", "r282", "r283", "r285", "r290", "r291", "r292", "r293", "r295", "r296", "r297", "r298", "r299", "r300", "r303", "r395", "r580", "r581", "r582", "r583", "r584", "r636" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureDebtFutureMinimumPrincipalPaymentsDetails", "http://www.petrospharma.com/role/DisclosureDebtPromissoryNoteDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredRevenue": { "auth_ref": [ "r629" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.", "label": "Deferred Revenue", "terseLabel": "Deferred Revenue" } } }, "localname": "DeferredRevenue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r4", "r200" ], "calculation": { "http://www.petrospharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.petrospharma.com/role/StatementCondensedConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation and amortization expense", "verboseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureSegmentInformationDetails", "http://www.petrospharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "http://www.petrospharma.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeGainLossOnDerivativeNet": { "auth_ref": [ "r660" ], "calculation": { "http://www.petrospharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://www.petrospharma.com/role/StatementCondensedConsolidatedStatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.", "label": "Change in Fair Value of Derivative Liability", "negatedLabel": "Derivative liability", "negatedTerseLabel": "Change in fair value of derivative liability", "terseLabel": "Change in fair value of derivative liability" } } }, "localname": "DerivativeGainLossOnDerivativeNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureSegmentInformationDetails", "http://www.petrospharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "http://www.petrospharma.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisaggregationOfRevenueLineItems": { "auth_ref": [ "r326", "r586", "r587", "r588", "r589", "r590", "r591", "r592" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Disaggregation of Revenue [Line Items]", "terseLabel": "Summary of Significant Accounting Policies" } } }, "localname": "DisaggregationOfRevenueLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTable": { "auth_ref": [ "r326", "r586", "r587", "r588", "r589", "r590", "r591", "r592" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table]" } } }, "localname": "DisaggregationOfRevenueTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r330", "r334", "r361", "r362", "r363", "r594" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-based Payment Arrangement [Text Block]", "verboseLabel": "Stock Options and Restricted Stock Units (\"RSU's\")" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureStockOptionsAndRestrictedStockUnitsrsuS" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock Options and Restricted Stock Units (\"RSU's\")" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Basic and Diluted Net Income (Loss) per Common Share", "terseLabel": "Net Income (loss) per common share" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r147", "r166", "r167", "r168", "r169", "r170", "r176", "r178", "r181", "r182", "r183", "r187", "r385", "r386", "r419", "r431", "r573" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Basic (in dollars per share)", "verboseLabel": "Basic net income (loss) per common share" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureBasicAndDilutedNetIncomeLossPerCommonShareReconciliationOfWeightedAverageNumberOfCommonSharesOutstandingUsedInCalculatingBasicAndDilutedNetLossPerShareDetails", "http://www.petrospharma.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r147", "r166", "r167", "r168", "r169", "r170", "r178", "r181", "r182", "r183", "r187", "r385", "r386", "r419", "r431", "r573" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Diluted (in dollars per share)", "verboseLabel": "Diluted net income (loss) per common share" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureBasicAndDilutedNetIncomeLossPerCommonShareReconciliationOfWeightedAverageNumberOfCommonSharesOutstandingUsedInCalculatingBasicAndDilutedNetLossPerShareDetails", "http://www.petrospharma.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r26", "r27" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Basic and Diluted Net Loss per Common Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r175", "r184", "r185", "r186" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Basic and Diluted Net Income (Loss) per Common Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureBasicAndDilutedNetIncomeLossPerCommonShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash": { "auth_ref": [ "r4" ], "calculation": { "http://www.petrospharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense (reversal of expense) for employee benefits and share-based payment arrangement. Includes, but is not limited to, pension, other postretirement, postemployment and termination benefits.", "label": "Employee Benefit and Share-Based Payment Arrangement, Noncash", "terseLabel": "Employee stock-based compensation" } } }, "localname": "EmployeeBenefitsAndShareBasedCompensationNoncash", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Stock Options", "terseLabel": "Stock Options" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureBasicAndDilutedNetIncomeLossPerCommonSharePotentiallyDilutiveSecuritiesConvertibleIntoCommonSharesThatWereExcludedFromCalculationOfDilutedNetIncomeLossPerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r8", "r124", "r144", "r145", "r146", "r161", "r162", "r163", "r165", "r171", "r173", "r188", "r235", "r236", "r315", "r364", "r365", "r366", "r368", "r369", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r388", "r389", "r390", "r391", "r392", "r393", "r408", "r444", "r445", "r446", "r459", "r525" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_EquityOwnershipPercentageExcludingConsolidatedEntityAndEquityMethodInvestee": { "auth_ref": [ "r623" ], "lang": { "en-us": { "role": { "documentation": "Percentage of ownership of equity interest excluding interest in entity that is consolidated and equity method investee.", "label": "Equity Ownership, Excluding Consolidated Entity and Equity Method Investee, Percentage", "terseLabel": "Percentage of interest on issued and our outstanding Common Stock" } } }, "localname": "EquityOwnershipPercentageExcludingConsolidatedEntityAndEquityMethodInvestee", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Finite-Lived Intangible Asset, Useful Life", "terseLabel": "Estimated useful lives of intangible assets" } } }, "localname": "FiniteLivedIntangibleAssetUsefulLife", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureIntangibleAssetsAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "auth_ref": [ "r97" ], "calculation": { "http://www.petrospharma.com/role/DisclosureIntangibleAssetsFutureAnnualAmortizationDetails": { "order": 2.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One", "verboseLabel": "2024" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureIntangibleAssetsFutureAnnualAmortizationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": { "auth_ref": [], "calculation": { "http://www.petrospharma.com/role/DisclosureIntangibleAssetsFutureAnnualAmortizationDetails": { "order": 1.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.", "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year", "terseLabel": "2023 (remaining 6 months)" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureIntangibleAssetsFutureAnnualAmortizationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "auth_ref": [ "r97" ], "calculation": { "http://www.petrospharma.com/role/DisclosureIntangibleAssetsFutureAnnualAmortizationDetails": { "order": 5.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four", "terseLabel": "2027" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureIntangibleAssetsFutureAnnualAmortizationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "auth_ref": [ "r97" ], "calculation": { "http://www.petrospharma.com/role/DisclosureIntangibleAssetsFutureAnnualAmortizationDetails": { "order": 4.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three", "verboseLabel": "2026" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureIntangibleAssetsFutureAnnualAmortizationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "auth_ref": [ "r97" ], "calculation": { "http://www.petrospharma.com/role/DisclosureIntangibleAssetsFutureAnnualAmortizationDetails": { "order": 3.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two", "verboseLabel": "2025" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureIntangibleAssetsFutureAnnualAmortizationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r252", "r253", "r254", "r255", "r417", "r418" ], "lang": { "en-us": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureIntangibleAssetsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "auth_ref": [ "r417" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Finite-Lived Intangible Assets [Line Items]", "terseLabel": "Intangible Assets" } } }, "localname": "FiniteLivedIntangibleAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureIntangibleAssetsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r45", "r47" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureIntangibleAssetsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r96", "r417" ], "calculation": { "http://www.petrospharma.com/role/DisclosureIntangibleAssetsFutureAnnualAmortizationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Net", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "terseLabel": "Carrying value of intangible assets", "totalLabel": "Total" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureIntangibleAssetsAdditionalInformationDetails", "http://www.petrospharma.com/role/DisclosureIntangibleAssetsDetails", "http://www.petrospharma.com/role/DisclosureIntangibleAssetsFutureAnnualAmortizationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Finite-lived Intangible Assets [Roll Forward]", "terseLabel": "Intangible Assets" } } }, "localname": "FiniteLivedIntangibleAssetsRollForward", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GainLossRelatedToLitigationSettlement": { "auth_ref": [ "r653" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.", "label": "Gain (Loss) Related to Litigation Settlement", "negatedLabel": "Gain on settlement with Vivus" } } }, "localname": "GainLossRelatedToLitigationSettlement", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureSegmentInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Intangible Assets" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined.", "label": "Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]", "terseLabel": "Intangible Assets" } } }, "localname": "GoodwillAndIntangibleAssetsIntangibleAssetsPolicy", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r85", "r157", "r195", "r215", "r221", "r224", "r234", "r265", "r266", "r268", "r269", "r270", "r272", "r274", "r276", "r277", "r387", "r575", "r654" ], "calculation": { "http://www.petrospharma.com/role/StatementCondensedConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit", "totalLabel": "Gross profit" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": { "auth_ref": [ "r634", "r650" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.", "label": "Impairment of Intangible Assets, Finite-Lived", "negatedLabel": "Intangible Impairment", "terseLabel": "Impairment charge of approximate" } } }, "localname": "ImpairmentOfIntangibleAssetsFinitelived", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureIntangibleAssetsAdditionalInformationDetails", "http://www.petrospharma.com/role/DisclosureIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r0", "r82", "r110", "r195", "r215", "r221", "r224", "r420", "r428", "r575" ], "calculation": { "http://www.petrospharma.com/role/StatementCondensedConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Loss before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r3" ], "calculation": { "http://www.petrospharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "verboseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r3" ], "calculation": { "http://www.petrospharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "auth_ref": [ "r3" ], "calculation": { "http://www.petrospharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.", "label": "Increase (Decrease) in Accrued Liabilities", "verboseLabel": "Accrued expenses" } } }, "localname": "IncreaseDecreaseInAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "auth_ref": [ "r415", "r633" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Increase (Decrease) in Contract with Customer, Liability", "terseLabel": "Increase in estimates of reserve" } } }, "localname": "IncreaseDecreaseInContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r3" ], "calculation": { "http://www.petrospharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedLabel": "Inventories" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "verboseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherCurrentLiabilities": { "auth_ref": [ "r633" ], "calculation": { "http://www.petrospharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in current liabilities classified as other.", "label": "Increase (Decrease) in Other Current Liabilities", "verboseLabel": "Other current liabilities" } } }, "localname": "IncreaseDecreaseInOtherCurrentLiabilities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": { "auth_ref": [], "calculation": { "http://www.petrospharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other.", "label": "Increase (Decrease) in Other Noncurrent Liabilities", "terseLabel": "Other long-term liabilities" } } }, "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r3" ], "calculation": { "http://www.petrospharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other current assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r251" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all or part of the information related to intangible assets.", "label": "Intangible Assets Disclosure [Text Block]", "terseLabel": "Intangible Assets" } } }, "localname": "IntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureIntangibleAssets" ], "xbrltype": "textBlockItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r43", "r46" ], "calculation": { "http://www.petrospharma.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible Assets, Net (Excluding Goodwill)", "terseLabel": "Intangible assets, net" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureSegmentInformationSegmentAssetsDetails", "http://www.petrospharma.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseDebt": { "auth_ref": [ "r89", "r298", "r306", "r583", "r584" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.", "label": "Interest Expense, Debt", "terseLabel": "Interest expense" } } }, "localname": "InterestExpenseDebt", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureSegmentInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestIncomeExpenseNet": { "auth_ref": [ "r112" ], "calculation": { "http://www.petrospharma.com/role/StatementCondensedConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net amount of operating interest income (expense).", "label": "Interest Income (Expense), Net", "terseLabel": "Interest income" } } }, "localname": "InterestIncomeExpenseNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestIncomeOperating": { "auth_ref": [ "r84", "r508", "r540", "r541", "r609", "r610", "r688" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of operating interest income, including, but not limited to, amortization and accretion of premiums and discounts on securities.", "label": "Interest Income, Operating", "negatedLabel": "Interest income" } } }, "localname": "InterestIncomeOperating", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureSegmentInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r149", "r152", "r153" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "verboseLabel": "Cash paid for interest during the period" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Inventories" } } }, "localname": "InventoryDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_InventoryDisclosureTextBlock": { "auth_ref": [ "r241" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.", "label": "Inventory Disclosure [Text Block]", "terseLabel": "Inventories" } } }, "localname": "InventoryDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureInventories" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "auth_ref": [ "r95", "r568" ], "calculation": { "http://www.petrospharma.com/role/DisclosureInventoriesDetails": { "order": 2.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.", "label": "Inventory, Finished Goods, Net of Reserves", "verboseLabel": "Finished goods" } } }, "localname": "InventoryFinishedGoodsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureInventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r139", "r566", "r599" ], "calculation": { "http://www.petrospharma.com/role/DisclosureInventoriesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.petrospharma.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "terseLabel": "Inventories", "totalLabel": "Total inventory" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureInventoriesDetails", "http://www.petrospharma.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNoncurrent": { "auth_ref": [ "r628" ], "calculation": { "http://www.petrospharma.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.", "label": "Inventory, Noncurrent", "terseLabel": "API purchase commitment" } } }, "localname": "InventoryNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryRawMaterialsNetOfReserves": { "auth_ref": [ "r95", "r569" ], "calculation": { "http://www.petrospharma.com/role/DisclosureInventoriesDetails": { "order": 1.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.", "label": "Inventory, Raw Materials, Net of Reserves", "verboseLabel": "Raw Materials" } } }, "localname": "InventoryRawMaterialsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureInventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCostAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Lease Cost:", "terseLabel": "Operating Lease Cost:" } } }, "localname": "LeaseCostAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureOperatingLeasesLeaseExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LeasesOperatingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Leases" } } }, "localname": "LeasesOperatingAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionLineItems": { "auth_ref": [ "r401" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Lessee, Lease, Description [Line Items]", "terseLabel": "Operating Leases" } } }, "localname": "LesseeLeaseDescriptionLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureOperatingLeasesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionTable": { "auth_ref": [ "r401" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about lessee's leases.", "label": "Lessee, Lease, Description [Table]" } } }, "localname": "LesseeLeaseDescriptionTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureOperatingLeasesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r666" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]", "terseLabel": "Summary of future minimum lease payments under non-cancelable leases" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureOperatingLeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r407" ], "calculation": { "http://www.petrospharma.com/role/DisclosureCommitmentsAndContingenciesMinimumLeasePaymentsDetailsCalc2": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee, Operating Lease, Liability, to be Paid", "totalLabel": "Total lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureOperatingLeasesFutureMinimumLeasePaymentsUnderNonCancelableLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r407" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "terseLabel": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureOperatingLeasesFutureMinimumLeasePaymentsUnderNonCancelableLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r407" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "terseLabel": "2026" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureOperatingLeasesFutureMinimumLeasePaymentsUnderNonCancelableLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r407" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "terseLabel": "2025" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureOperatingLeasesFutureMinimumLeasePaymentsUnderNonCancelableLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "auth_ref": [ "r666" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.", "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year", "terseLabel": "2023 (remaining 6 months)" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureOperatingLeasesFutureMinimumLeasePaymentsUnderNonCancelableLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r407" ], "calculation": { "http://www.petrospharma.com/role/DisclosureCommitmentsAndContingenciesMinimumLeasePaymentsDetailsCalc2": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedLabel": "Less: Imputed Interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureOperatingLeasesFutureMinimumLeasePaymentsUnderNonCancelableLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": { "auth_ref": [ "r665" ], "lang": { "en-us": { "role": { "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Remaining Lease Term", "terseLabel": "Remaining lease terms" } } }, "localname": "LesseeOperatingLeaseRemainingLeaseTerm", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureOperatingLeasesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r396" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "Lessee, Operating Leases [Text Block]", "verboseLabel": "Operating Leases" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureOperatingLeases" ], "xbrltype": "textBlockItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r17", "r157", "r234", "r265", "r266", "r268", "r269", "r270", "r272", "r274", "r276", "r277", "r373", "r376", "r377", "r387", "r483", "r574", "r612", "r654", "r667", "r668" ], "calculation": { "http://www.petrospharma.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r77", "r109", "r426", "r599", "r637", "r648", "r663" ], "calculation": { "http://www.petrospharma.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total Liabilities and Stockholders' Equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities and Stockholders' Equity" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r19", "r128", "r157", "r234", "r265", "r266", "r268", "r269", "r270", "r272", "r274", "r276", "r277", "r373", "r376", "r377", "r387", "r599", "r654", "r667", "r668" ], "calculation": { "http://www.petrospharma.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LoansNotesTradeAndOtherReceivablesExcludingAllowanceForCreditLossesTextBlock": { "auth_ref": [ "r647" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for claims held for amounts due a company, excluding disclosure for allowance for credit losses. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Also excludes disclosure for financing receivables.", "label": "Loans, Notes, Trade and Other Receivables, Excluding Allowance for Credit Losses [Text Block]", "terseLabel": "Accounts Receivable, net" } } }, "localname": "LoansNotesTradeAndOtherReceivablesExcludingAllowanceForCreditLossesTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureAccountsReceivableNet" ], "xbrltype": "textBlockItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r13", "r108", "r291", "r305", "r581", "r582", "r676" ], "calculation": { "http://www.petrospharma.com/role/DisclosureDebtFutureMinimumPrincipalPaymentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.", "label": "Long-term Debt", "totalLabel": "Total" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureDebtFutureMinimumPrincipalPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtCurrent": { "auth_ref": [ "r132" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation.", "label": "Long-term Debt, Current Maturities", "negatedLabel": "Less: current portion", "terseLabel": "Debt" } } }, "localname": "LongTermDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureDebtFutureMinimumPrincipalPaymentsDetails", "http://www.petrospharma.com/role/DisclosureNatureOfOperationsBasisOfPresentationLiquidityAndGoingConcernAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "auth_ref": [ "r6", "r160", "r296" ], "calculation": { "http://www.petrospharma.com/role/DisclosureDebtFutureMinimumPrincipalPaymentsDetails": { "order": 4.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year One", "terseLabel": "2024" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureDebtFutureMinimumPrincipalPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": { "auth_ref": [ "r6", "r160", "r296" ], "calculation": { "http://www.petrospharma.com/role/DisclosureDebtFutureMinimumPrincipalPaymentsDetails": { "order": 1.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Four", "terseLabel": "2027" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureDebtFutureMinimumPrincipalPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": { "auth_ref": [ "r6", "r160", "r296" ], "calculation": { "http://www.petrospharma.com/role/DisclosureDebtFutureMinimumPrincipalPaymentsDetails": { "order": 2.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Three", "terseLabel": "2026" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureDebtFutureMinimumPrincipalPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "auth_ref": [ "r6", "r160", "r296" ], "calculation": { "http://www.petrospharma.com/role/DisclosureDebtFutureMinimumPrincipalPaymentsDetails": { "order": 3.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Two", "terseLabel": "2025" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureDebtFutureMinimumPrincipalPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear": { "auth_ref": [ "r638" ], "calculation": { "http://www.petrospharma.com/role/DisclosureDebtFutureMinimumPrincipalPaymentsDetails": { "order": 5.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year.", "label": "Long-Term Debt, Maturity, Remainder of Fiscal Year", "terseLabel": "2023 (remaining 6 months)" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureDebtFutureMinimumPrincipalPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtNoncurrent": { "auth_ref": [ "r133" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.", "label": "Long-term Debt, Excluding Current Maturities", "totalLabel": "Promissory note, net of current portion" } } }, "localname": "LongTermDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureDebtFutureMinimumPrincipalPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermNotesPayable": { "auth_ref": [ "r21" ], "calculation": { "http://www.petrospharma.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.", "label": "Notes Payable, Noncurrent", "terseLabel": "Promissory note, net of current portion" } } }, "localname": "LongTermNotesPayable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r151" ], "calculation": { "http://www.petrospharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash used in financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "verboseLabel": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r90", "r91", "r92" ], "calculation": { "http://www.petrospharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "verboseLabel": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r83", "r92", "r111", "r126", "r142", "r143", "r146", "r157", "r164", "r166", "r167", "r168", "r169", "r172", "r173", "r180", "r195", "r215", "r221", "r224", "r234", "r265", "r266", "r268", "r269", "r270", "r272", "r274", "r276", "r277", "r386", "r387", "r430", "r506", "r523", "r524", "r575", "r610", "r654" ], "calculation": { "http://www.petrospharma.com/role/StatementCondensedConsolidatedStatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net loss", "totalLabel": "Net Income (loss)", "verboseLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureBasicAndDilutedNetIncomeLossPerCommonShareReconciliationOfWeightedAverageNumberOfCommonSharesOutstandingUsedInCalculatingBasicAndDilutedNetLossPerShareDetails", "http://www.petrospharma.com/role/DisclosureSegmentInformationDetails", "http://www.petrospharma.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity", "http://www.petrospharma.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recent Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NonUsMember": { "auth_ref": [ "r684", "r685", "r686", "r687" ], "lang": { "en-us": { "role": { "documentation": "Countries excluding the United States of America (US).", "label": "International" } } }, "localname": "NonUsMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureSegmentInformationNetSalesByGeographicRegionDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Noncash Investing and Financing Items [Abstract]", "terseLabel": "Noncash Items:" } } }, "localname": "NoncashInvestingAndFinancingItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NotesPayableCurrent": { "auth_ref": [ "r16" ], "calculation": { "http://www.petrospharma.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.", "label": "Notes Payable, Current", "terseLabel": "Current portion of promissory note" } } }, "localname": "NotesPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesPayableOtherPayablesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A written promise to pay a note to a third party.", "label": "Note", "verboseLabel": "Promissory note" } } }, "localname": "NotesPayableOtherPayablesMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureDebtFutureMinimumPrincipalPaymentsDetails", "http://www.petrospharma.com/role/DisclosureDebtPromissoryNoteDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NumberOfOperatingSegments": { "auth_ref": [ "r645" ], "lang": { "en-us": { "role": { "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.", "label": "Number of Operating Segments" } } }, "localname": "NumberOfOperatingSegments", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureSegmentInformationDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://www.petrospharma.com/role/StatementCondensedConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r195", "r215", "r221", "r224", "r575" ], "calculation": { "http://www.petrospharma.com/role/StatementCondensedConsolidatedStatementsOfOperations": { "order": 4.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r402", "r598" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating Lease, Cost", "terseLabel": "Fixed lease cost" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureOperatingLeasesLeaseExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseExpense": { "auth_ref": [ "r664" ], "calculation": { "http://www.petrospharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating lease expense. Excludes sublease income.", "label": "Operating Lease, Expense", "verboseLabel": "Lease expense" } } }, "localname": "OperatingLeaseExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Future minimum lease payments under non-cancelable leases", "terseLabel": "Lease Liability Maturity Analysis" } } }, "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureOperatingLeasesFutureMinimumLeasePaymentsUnderNonCancelableLeasesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r398" ], "calculation": { "http://www.petrospharma.com/role/DisclosureCommitmentsAndContingenciesMinimumLeasePaymentsDetailsCalc2": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 }, "http://www.petrospharma.com/role/DisclosureOperatingLeasesSupplementalBalanceSheetInformationRelatedToLeasesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "totalLabel": "Total" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureOperatingLeasesFutureMinimumLeasePaymentsUnderNonCancelableLeasesDetails", "http://www.petrospharma.com/role/DisclosureOperatingLeasesSupplementalBalanceSheetInformationRelatedToLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating lease liability:", "terseLabel": "Operating lease liability:" } } }, "localname": "OperatingLeaseLiabilityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureOperatingLeasesSupplementalBalanceSheetInformationRelatedToLeasesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r398" ], "calculation": { "http://www.petrospharma.com/role/DisclosureOperatingLeasesSupplementalBalanceSheetInformationRelatedToLeasesDetails": { "order": 1.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Operating lease liability, current" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureOperatingLeasesSupplementalBalanceSheetInformationRelatedToLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": { "auth_ref": [ "r399" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of financial position that includes current operating lease liability.", "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]", "terseLabel": "Other current liabilities" } } }, "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureOperatingLeasesSupplementalBalanceSheetInformationRelatedToLeasesDetails" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r398" ], "calculation": { "http://www.petrospharma.com/role/DisclosureOperatingLeasesSupplementalBalanceSheetInformationRelatedToLeasesDetails": { "order": 2.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Operating lease liability, noncurrent" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureOperatingLeasesSupplementalBalanceSheetInformationRelatedToLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": { "auth_ref": [ "r399" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of financial position that includes noncurrent operating lease liability.", "label": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]", "terseLabel": "Other long-term liabilities" } } }, "localname": "OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureOperatingLeasesSupplementalBalanceSheetInformationRelatedToLeasesDetails" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r400", "r404" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease, Payments", "terseLabel": "Operating cash flows from operating leases" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureOperatingLeasesSupplementalLeaseTermAndDiscountRateInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r397" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating lease ROU asset:" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureOperatingLeasesSupplementalBalanceSheetInformationRelatedToLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": { "auth_ref": [ "r399" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of financial position that includes operating lease right-of-use asset.", "label": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]", "terseLabel": "Other assets" } } }, "localname": "OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureOperatingLeasesSupplementalBalanceSheetInformationRelatedToLeasesDetails" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r406", "r598" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Weighted-average discount rate - operating leases" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureOperatingLeasesSupplementalLeaseTermAndDiscountRateInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r405", "r598" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Weighted-average remaining lease terms - operating leases" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureOperatingLeasesSupplementalLeaseTermAndDiscountRateInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OperatingSegmentsMember": { "auth_ref": [ "r214", "r215", "r216", "r217", "r218", "r224" ], "lang": { "en-us": { "role": { "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Operating segments" } } }, "localname": "OperatingSegmentsMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureSegmentInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Nature of Operations, Basis of Presentation, Liquidity and Going Concern" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r68", "r104", "r450", "r451" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "terseLabel": "Nature of Operations, Basis of Presentation, Liquidity and Going Concern" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureNatureOfOperationsBasisOfPresentationLiquidityAndGoingConcern" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r18" ], "calculation": { "http://www.petrospharma.com/role/DisclosureAccruedExpensesDetails": { "order": 6.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Accrued Liabilities, Current", "terseLabel": "Other accrued expenses" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsCurrent": { "auth_ref": [ "r140", "r599" ], "calculation": { "http://www.petrospharma.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current assets classified as other.", "label": "Other Assets, Current", "terseLabel": "Other current assets" } } }, "localname": "OtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r130" ], "calculation": { "http://www.petrospharma.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCurrentAssetsMember": { "auth_ref": [ "r56", "r58" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other current assets.", "label": "Other Current Assets [Member]", "verboseLabel": "Other Current Assets" } } }, "localname": "OtherCurrentAssetsMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureMarketingLicensingAndDistributionAgreementsVivusDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherLiabilitiesCurrent": { "auth_ref": [ "r18", "r599" ], "calculation": { "http://www.petrospharma.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Current", "terseLabel": "Other current liabilities" } } }, "localname": "OtherLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r22" ], "calculation": { "http://www.petrospharma.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Other long-term liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncurrentAssetsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other noncurrent assets.", "label": "Other Noncurrent Assets [Member]", "verboseLabel": "Other Noncurrent Assets" } } }, "localname": "OtherNoncurrentAssetsMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureMarketingLicensingAndDistributionAgreementsVivusDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherPrepaidExpenseCurrent": { "auth_ref": [ "r630", "r649" ], "calculation": { "http://www.petrospharma.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Other Prepaid Expense, Current", "terseLabel": "Other prepaid expenses" } } }, "localname": "OtherPrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockConvertibleConversionPrice": { "auth_ref": [ "r309" ], "lang": { "en-us": { "role": { "documentation": "Per share conversion price of preferred stock.", "label": "Preferred Stock, Convertible, Conversion Price", "terseLabel": "Initial conversion price" } } }, "localname": "PreferredStockConvertibleConversionPrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockConvertibleSharesIssuable": { "auth_ref": [ "r309" ], "lang": { "en-us": { "role": { "documentation": "Number of common shares issuable upon conversion of preferred stock.", "label": "Preferred Stock, Convertible, Shares Issuable", "terseLabel": "Maximum shares issuable upon conversion" } } }, "localname": "PreferredStockConvertibleSharesIssuable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockDividendRatePercentage": { "auth_ref": [ "r308", "r529", "r532", "r534", "r539" ], "lang": { "en-us": { "role": { "documentation": "The percentage rate used to calculate dividend payments on preferred stock.", "label": "Preferred Stock, Dividend Rate, Percentage", "terseLabel": "Dividend rate" } } }, "localname": "PreferredStockDividendRatePercentage", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r71", "r307" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureSubsequentEventsDetails", "http://www.petrospharma.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PrepaidExpenseAndOtherAssets": { "auth_ref": [], "calculation": { "http://www.petrospharma.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets.", "label": "Prepaid Expense and Other Assets", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r631" ], "calculation": { "http://www.petrospharma.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "totalLabel": "Total prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidInsurance": { "auth_ref": [ "r567", "r578", "r649" ], "calculation": { "http://www.petrospharma.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails": { "order": 4.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Insurance", "terseLabel": "Prepaid insurance" } } }, "localname": "PrepaidInsurance", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrivatePlacementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts.", "label": "Private Placement", "terseLabel": "Private Placement" } } }, "localname": "PrivatePlacementMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": { "auth_ref": [ "r2" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.", "label": "Proceeds from Issuance of Private Placement", "terseLabel": "Proceeds from gross proceeds" } } }, "localname": "ProceedsFromIssuanceOfPrivatePlacement", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureNatureOfOperationsBasisOfPresentationLiquidityAndGoingConcernAdditionalInformationDetails", "http://www.petrospharma.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromRepaymentsOfNotesPayable": { "auth_ref": [], "calculation": { "http://www.petrospharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from long-term debt supported by a written promise to pay an obligation.", "label": "Proceeds from (Repayments of) Notes Payable", "terseLabel": "Payment of promissory note" } } }, "localname": "ProceedsFromRepaymentsOfNotesPayable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r126", "r142", "r143", "r150", "r157", "r164", "r172", "r173", "r195", "r215", "r221", "r224", "r234", "r265", "r266", "r268", "r269", "r270", "r272", "r274", "r276", "r277", "r371", "r374", "r375", "r386", "r387", "r420", "r429", "r458", "r506", "r523", "r524", "r575", "r596", "r597", "r611", "r632", "r654" ], "calculation": { "http://www.petrospharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net income (loss)" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r5", "r421", "r427", "r599" ], "calculation": { "http://www.petrospharma.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Fixed assets, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProvisionForDoubtfulAccounts": { "auth_ref": [ "r148", "r239" ], "calculation": { "http://www.petrospharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.", "label": "Accounts Receivable, Credit Loss Expense (Reversal)", "terseLabel": "Bad debt expense (recoveries)" } } }, "localname": "ProvisionForDoubtfulAccounts", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable": { "auth_ref": [ "r39", "r40" ], "lang": { "en-us": { "role": { "documentation": "Identification, description, and amounts of all significant reconciling items in the reconciliation of total assets from reportable segments to the entity's consolidated assets.", "label": "Reconciliation of Assets from Segment to Consolidated [Table]" } } }, "localname": "ReconciliationOfAssetsFromSegmentToConsolidatedTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureSegmentInformationSegmentAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock": { "auth_ref": [ "r39", "r40" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of all significant reconciling items in the reconciliation of total assets from reportable segments to the entity's consolidated assets.", "label": "Reconciliation of Assets from Segment to Consolidated [Table Text Block]", "terseLabel": "Summary of assets by reportable segment and reconciliation of segment assets to consolidated assets" } } }, "localname": "ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureSegmentInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r67", "r367", "r675" ], "calculation": { "http://www.petrospharma.com/role/StatementCondensedConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development expense", "verboseLabel": "Research and development expenses" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureSegmentInformationDetails", "http://www.petrospharma.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureStockOptionsAndRestrictedStockUnitsrsuSAdditionalInformationDetails", "http://www.petrospharma.com/role/DisclosureStockOptionsAndRestrictedStockUnitsrsuSSummaryOfStockOptionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r74", "r102", "r425", "r447", "r448", "r457", "r485", "r599" ], "calculation": { "http://www.petrospharma.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated undistributed earnings (deficit).", "label": "Retained Earnings (Accumulated Deficit)", "negatedTerseLabel": "Accumulated deficit", "verboseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureNatureOfOperationsBasisOfPresentationLiquidityAndGoingConcernAdditionalInformationDetails", "http://www.petrospharma.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r124", "r161", "r162", "r163", "r165", "r171", "r173", "r235", "r236", "r364", "r365", "r366", "r368", "r369", "r378", "r380", "r381", "r383", "r384", "r444", "r446", "r459", "r682" ], "lang": { "en-us": { "role": { "documentation": "Accumulated undistributed earnings (deficit).", "label": "Accumulated Deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r196", "r197", "r214", "r219", "r220", "r226", "r228", "r230", "r325", "r326", "r416" ], "calculation": { "http://www.petrospharma.com/role/StatementCondensedConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Net sales" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureSegmentInformationDetails", "http://www.petrospharma.com/role/DisclosureSegmentInformationNetSalesByGeographicRegionDetails", "http://www.petrospharma.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerMember": { "auth_ref": [ "r230", "r624" ], "lang": { "en-us": { "role": { "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation.", "label": "Gross billings from customers" } } }, "localname": "RevenueFromContractWithCustomerMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureAccountsReceivableNetAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "auth_ref": [ "r121", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r563" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue from contract with customer.", "label": "Revenue from Contract with Customer [Policy Text Block]", "terseLabel": "Revenue Recognition" } } }, "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.", "label": "Revenue from External Customers by Geographic Areas [Table Text Block]", "terseLabel": "Summary of net sales by geographic region" } } }, "localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureSegmentInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenuePracticalExpedientFinancingComponent": { "auth_ref": [ "r324" ], "lang": { "en-us": { "role": { "documentation": "Indicates (true false) whether practical expedient was elected not to adjust consideration for effect of financing component when transfer and customer payment for product or service occurs within one year or less.", "label": "Revenue, Practical Expedient, Financing Component [true false]", "terseLabel": "Revenue practical expedient, financing component" } } }, "localname": "RevenuePracticalExpedientFinancingComponent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "booleanItemType" }, "us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Revenues from External Customers and Long-Lived Assets" } } }, "localname": "RevenuesFromExternalCustomersAndLongLivedAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureSegmentInformationNetSalesByGeographicRegionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RoyaltyExpense": { "auth_ref": [ "r87" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.", "label": "Royalty Expense", "terseLabel": "Royalty incurred" } } }, "localname": "RoyaltyExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureMarketingLicensingAndDistributionAgreementsVivusDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale of Stock [Domain]", "terseLabel": "Sale of Stock [Domain]" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": { "auth_ref": [ "r24" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.", "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]", "terseLabel": "Schedule of accounts receivable" } } }, "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureAccountsReceivableNetTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accrued liabilities.", "label": "Schedule of Accrued Liabilities [Table Text Block]", "terseLabel": "Schedule of accrued expenses" } } }, "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureAccruedExpensesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r26" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureBasicAndDilutedNetIncomeLossPerCommonSharePotentiallyDilutiveSecuritiesConvertibleIntoCommonSharesThatWereExcludedFromCalculationOfDilutedNetIncomeLossPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r26" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Summary of potentially dilutive securities convertible into common shares" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureBasicAndDilutedNetIncomeLossPerCommonShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "auth_ref": [ "r370" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]" } } }, "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureMarketingLicensingAndDistributionAgreementsVivusDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfDebtTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.", "label": "Schedule of Debt [Table Text Block]", "terseLabel": "Schedule of future principal payments of the promissory note" } } }, "localname": "ScheduleOfDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureDebtTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r644" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Summary of basic and diluted net loss per share" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureBasicAndDilutedNetIncomeLossPerCommonShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "auth_ref": [ "r45", "r47", "r417" ], "lang": { "en-us": { "role": { "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Schedule of Finite-Lived Intangible Assets [Table]" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureIntangibleAssetsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "auth_ref": [ "r45", "r47" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.", "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]", "terseLabel": "Schedule of intangible assets" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureIntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r14", "r78", "r79", "r80" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Schedule of Inventory, Current [Table Text Block]", "terseLabel": "Schedule of Inventories" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureInventoriesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable": { "auth_ref": [ "r41", "r81" ], "lang": { "en-us": { "role": { "documentation": "Schedule of material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries.", "label": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]" } } }, "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureSegmentInformationNetSalesByGeographicRegionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "auth_ref": [ "r36", "r37", "r38", "r42" ], "lang": { "en-us": { "role": { "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table]" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureSegmentInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "auth_ref": [ "r36", "r37", "r38", "r42" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]", "terseLabel": "Summary of results of operations by reportable segment" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureSegmentInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r331", "r333", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureStockOptionsAndRestrictedStockUnitsrsuSAdditionalInformationDetails", "http://www.petrospharma.com/role/DisclosureStockOptionsAndRestrictedStockUnitsrsuSSummaryOfStockOptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r9", "r10", "r53" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]", "verboseLabel": "Schedule of stock options" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureStockOptionsAndRestrictedStockUnitsrsuSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": { "auth_ref": [ "r51" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.", "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]", "verboseLabel": "Schedule of warrants" } } }, "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureCommonStockWarrantsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": { "auth_ref": [ "r47" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.", "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]", "terseLabel": "Schedule of future annual amortization related to the company's intangible assets" } } }, "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureIntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentDomain": { "auth_ref": [ "r192", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r224", "r230", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r257", "r258", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r579", "r626", "r678" ], "lang": { "en-us": { "role": { "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Segments [Domain]" } } }, "localname": "SegmentDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureSegmentInformationDetails", "http://www.petrospharma.com/role/DisclosureSegmentInformationSegmentAssetsDetails", "http://www.petrospharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentReportingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Segment Information" } } }, "localname": "SegmentReportingAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingAssetReconcilingItemLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Segment Reporting, Asset Reconciling Item" } } }, "localname": "SegmentReportingAssetReconcilingItemLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureSegmentInformationSegmentAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r191", "r192", "r193", "r194", "r195", "r207", "r218", "r222", "r223", "r224", "r225", "r226", "r227", "r230" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "Segment Reporting Disclosure [Text Block]", "terseLabel": "Segment Information" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureSegmentInformation" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Segment Information [Line Items]", "terseLabel": "Segment Information" } } }, "localname": "SegmentReportingInformationLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureSegmentInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingInformationProfitLossAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Results of operations by reportable segment" } } }, "localname": "SegmentReportingInformationProfitLossAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureSegmentInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "auth_ref": [ "r208", "r209", "r210", "r211", "r212", "r213", "r228", "r576" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for segment reporting.", "label": "Segment Reporting, Policy [Policy Text Block]", "terseLabel": "Segment Reporting" } } }, "localname": "SegmentReportingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r88" ], "calculation": { "http://www.petrospharma.com/role/StatementCondensedConsolidatedStatementsOfOperations": { "order": 4.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, General and Administrative Expense", "terseLabel": "Selling, general and administrative", "verboseLabel": "Selling, general and administrative expenses" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureSegmentInformationDetails", "http://www.petrospharma.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r3" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Payment Arrangement, Noncash Expense", "terseLabel": "Stock-based compensation expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureStockOptionsAndRestrictedStockUnitsrsuSAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r594" ], "lang": { "en-us": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period", "verboseLabel": "Vesting period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureStockOptionsAndRestrictedStockUnitsrsuSAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [ "r331", "r333", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureStockOptionsAndRestrictedStockUnitsrsuSAdditionalInformationDetails", "http://www.petrospharma.com/role/DisclosureStockOptionsAndRestrictedStockUnitsrsuSSummaryOfStockOptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized", "terseLabel": "Options to purchase shares of common stock" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureStockOptionsAndRestrictedStockUnitsrsuSAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "auth_ref": [ "r595" ], "lang": { "en-us": { "role": { "documentation": "Number of shares authorized for issuance under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized", "verboseLabel": "Number of shares authorized" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureStockOptionsAndRestrictedStockUnitsrsuSDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r52" ], "lang": { "en-us": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant", "verboseLabel": "Number of shares available for issuance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureStockOptionsAndRestrictedStockUnitsrsuSDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]", "verboseLabel": "Weighted-Average Remaining Contractual Term (Years) and Aggregate Intrinsic Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureStockOptionsAndRestrictedStockUnitsrsuSSummaryOfStockOptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r340" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number", "verboseLabel": "Options and RSU's exercisable at the end" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureStockOptionsAndRestrictedStockUnitsrsuSSummaryOfStockOptionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r340" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "verboseLabel": "Options exercisable at the end (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureStockOptionsAndRestrictedStockUnitsrsuSSummaryOfStockOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "auth_ref": [ "r345" ], "lang": { "en-us": { "role": { "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period", "negatedLabel": "Less: options and RSU's expired/cancelled" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureStockOptionsAndRestrictedStockUnitsrsuSSummaryOfStockOptionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [ "r342" ], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Number of options granted", "verboseLabel": "Options granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureStockOptionsAndRestrictedStockUnitsrsuSAdditionalInformationDetails", "http://www.petrospharma.com/role/DisclosureStockOptionsAndRestrictedStockUnitsrsuSSummaryOfStockOptionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r52" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value", "terseLabel": "Options outstanding at the end (in dollars)", "verboseLabel": "Options outstanding and exercisable at the beginning (in dollars)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureStockOptionsAndRestrictedStockUnitsrsuSSummaryOfStockOptionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r338", "r339" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Options and RSU's outstanding at the end", "periodStartLabel": "Options outstanding and exercisable on beginning" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureStockOptionsAndRestrictedStockUnitsrsuSSummaryOfStockOptionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]", "verboseLabel": "Number of Shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureStockOptionsAndRestrictedStockUnitsrsuSSummaryOfStockOptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r338", "r339" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Options outstanding at the end (in dollars per share)", "periodStartLabel": "Options outstanding and exercisable at the beginning (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureStockOptionsAndRestrictedStockUnitsrsuSSummaryOfStockOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]", "verboseLabel": "Weighted-Average Fair Value at Grant Date" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureStockOptionsAndRestrictedStockUnitsrsuSSummaryOfStockOptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased": { "auth_ref": [ "r52" ], "lang": { "en-us": { "role": { "documentation": "Per share weighted-average price paid for shares purchased on open market for issuance under share-based payment arrangement.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Per Share Weighted Average Price of Shares Purchased", "terseLabel": "Options to exercise price of common stock" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureStockOptionsAndRestrictedStockUnitsrsuSAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureStockOptionsAndRestrictedStockUnitsrsuSAdditionalInformationDetails", "http://www.petrospharma.com/role/DisclosureStockOptionsAndRestrictedStockUnitsrsuSSummaryOfStockOptionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r345" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price", "verboseLabel": "Less: options expired/cancelled (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureStockOptionsAndRestrictedStockUnitsrsuSSummaryOfStockOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r342" ], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Exercise price", "verboseLabel": "Options granted (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureStockOptionsAndRestrictedStockUnitsrsuSAdditionalInformationDetails", "http://www.petrospharma.com/role/DisclosureStockOptionsAndRestrictedStockUnitsrsuSSummaryOfStockOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": { "auth_ref": [ "r659" ], "lang": { "en-us": { "role": { "documentation": "Percentage of vesting of award under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage", "verboseLabel": "Vesting percentage" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureStockOptionsAndRestrictedStockUnitsrsuSAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r52" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "verboseLabel": "Options exercisable at the end (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureStockOptionsAndRestrictedStockUnitsrsuSSummaryOfStockOptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of increase (decrease) of non-vested options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Number of Shares, Period Increase (Decrease)", "terseLabel": "Number of shares increased for issuance" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureStockOptionsAndRestrictedStockUnitsrsuSDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r103" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Options and RSU's outstanding at the ending (in years)", "verboseLabel": "Options and RSU's outstanding at the beginning (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureStockOptionsAndRestrictedStockUnitsrsuSSummaryOfStockOptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of options vested.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares", "negatedLabel": "Less: RSU's vested" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureStockOptionsAndRestrictedStockUnitsrsuSSummaryOfStockOptionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average grant-date fair value of options vested.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value", "terseLabel": "Less: RSU's vested" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureStockOptionsAndRestrictedStockUnitsrsuSSummaryOfStockOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Balance (in shares)", "periodStartLabel": "Balance (in shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r93", "r155" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Summary of Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureSummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementBusinessSegmentsAxis": { "auth_ref": [ "r125", "r192", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r224", "r230", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r256", "r257", "r258", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r579", "r626", "r678" ], "lang": { "en-us": { "role": { "documentation": "Information by business segments.", "label": "Segments [Axis]" } } }, "localname": "StatementBusinessSegmentsAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureSegmentInformationDetails", "http://www.petrospharma.com/role/DisclosureSegmentInformationSegmentAssetsDetails", "http://www.petrospharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r123", "r134", "r135", "r136", "r157", "r178", "r179", "r181", "r183", "r189", "r190", "r234", "r265", "r268", "r269", "r270", "r276", "r277", "r307", "r308", "r311", "r312", "r313", "r387", "r453", "r454", "r455", "r456", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r471", "r484", "r507", "r525", "r543", "r544", "r545", "r546", "r547", "r620", "r635", "r643" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]", "terseLabel": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r8", "r23", "r124", "r144", "r145", "r146", "r161", "r162", "r163", "r165", "r171", "r173", "r188", "r235", "r236", "r315", "r364", "r365", "r366", "r368", "r369", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r388", "r389", "r390", "r391", "r392", "r393", "r408", "r444", "r445", "r446", "r459", "r525" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [ "r161", "r162", "r163", "r188", "r416", "r452", "r471", "r477", "r478", "r479", "r480", "r481", "r482", "r484", "r487", "r488", "r489", "r490", "r491", "r494", "r495", "r496", "r497", "r499", "r500", "r501", "r502", "r503", "r505", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r525", "r604" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONDENSED CONSOLIDATED BALANCE SHEETS" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r161", "r162", "r163", "r188", "r416", "r452", "r471", "r477", "r478", "r479", "r480", "r481", "r482", "r484", "r487", "r488", "r489", "r490", "r491", "r494", "r495", "r496", "r497", "r499", "r500", "r501", "r502", "r503", "r505", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r525", "r604" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r72", "r75", "r76", "r94", "r486", "r504", "r526", "r527", "r599", "r612", "r637", "r648", "r663", "r682" ], "calculation": { "http://www.petrospharma.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "totalLabel": "Total Stockholders' Equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/StatementCondensedConsolidatedBalanceSheets", "http://www.petrospharma.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Stockholders' Equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_SubleaseIncome": { "auth_ref": [ "r403", "r598" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of sublease income excluding finance and operating lease expense.", "label": "Sublease Income", "terseLabel": "Amount of fixed lease cost which are offset by sublease income" } } }, "localname": "SubleaseIncome", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureOperatingLeasesLeaseExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SubsequentEventLineItems": { "auth_ref": [ "r394", "r411" ], "lang": { "en-us": { "role": { "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.", "label": "Subsequent Event", "terseLabel": "Subsequent Events" } } }, "localname": "SubsequentEventLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r394", "r411" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent event", "terseLabel": "Subsequent event" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureNatureOfOperationsBasisOfPresentationLiquidityAndGoingConcernAdditionalInformationDetails", "http://www.petrospharma.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTable": { "auth_ref": [ "r394", "r411" ], "lang": { "en-us": { "role": { "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.", "label": "Subsequent Event [Table]", "terseLabel": "Subsequent Event [Table]" } } }, "localname": "SubsequentEventTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r394", "r411" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]", "terseLabel": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureNatureOfOperationsBasisOfPresentationLiquidityAndGoingConcernAdditionalInformationDetails", "http://www.petrospharma.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r394", "r411" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureNatureOfOperationsBasisOfPresentationLiquidityAndGoingConcernAdditionalInformationDetails", "http://www.petrospharma.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events." } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r410", "r412" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "terseLabel": "Subsequent Event" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureSubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]", "terseLabel": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "verboseLabel": "Supplemental cash flow information:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r370" ], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureMarketingLicensingAndDistributionAgreementsVivusDetails", "http://www.petrospharma.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r33", "r34", "r35", "r115", "r117", "r119", "r120" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_WarrantMember": { "auth_ref": [ "r601", "r602", "r605", "r606", "r607", "r608" ], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrants", "terseLabel": "Warrants" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureBasicAndDilutedNetIncomeLossPerCommonSharePotentiallyDilutiveSecuritiesConvertibleIntoCommonSharesThatWereExcludedFromCalculationOfDilutedNetIncomeLossPerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantsAndRightsNoteDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Stock Warrants" } } }, "localname": "WarrantsAndRightsNoteDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_WarrantsAndRightsOutstandingTerm": { "auth_ref": [ "r662" ], "lang": { "en-us": { "role": { "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Warrants and Rights Outstanding, Term", "terseLabel": "Warrants term" } } }, "localname": "WarrantsAndRightsOutstandingTerm", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r177", "r183" ], "calculation": { "http://www.petrospharma.com/role/DisclosureBasicAndDilutedNetIncomeLossPerCommonShareReconciliationOfWeightedAverageNumberOfCommonSharesOutstandingUsedInCalculatingBasicAndDilutedNetLossPerShareDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "totalLabel": "Weighted-average common shares for diluted net income ( loss) per unit", "verboseLabel": "Diluted" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureBasicAndDilutedNetIncomeLossPerCommonShareReconciliationOfWeightedAverageNumberOfCommonSharesOutstandingUsedInCalculatingBasicAndDilutedNetLossPerShareDetails", "http://www.petrospharma.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]", "terseLabel": "Weighted average common shares outstanding" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureBasicAndDilutedNetIncomeLossPerCommonShareReconciliationOfWeightedAverageNumberOfCommonSharesOutstandingUsedInCalculatingBasicAndDilutedNetLossPerShareDetails", "http://www.petrospharma.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r176", "r183" ], "calculation": { "http://www.petrospharma.com/role/DisclosureBasicAndDilutedNetIncomeLossPerCommonShareReconciliationOfWeightedAverageNumberOfCommonSharesOutstandingUsedInCalculatingBasicAndDilutedNetLossPerShareDetails": { "order": 1.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted-average common shares for basic net income ( loss) per unit", "verboseLabel": "Basic" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.petrospharma.com/role/DisclosureBasicAndDilutedNetIncomeLossPerCommonShareReconciliationOfWeightedAverageNumberOfCommonSharesOutstandingUsedInCalculatingBasicAndDilutedNetLossPerShareDetails", "http://www.petrospharma.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "sharesItemType" } }, "unitCount": 8 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r104": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "https://asc.fasb.org//810/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.10)", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "808", "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "808", "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "a", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r121": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "https://asc.fasb.org//606/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r122": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "808", "URI": "https://asc.fasb.org//808/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r123": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "205", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(5))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r175": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "https://asc.fasb.org//260/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r191": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "280", "URI": "https://asc.fasb.org//280/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(j)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "26", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-26", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "34", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-34", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479344/326-20-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.3,4)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r241": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "https://asc.fasb.org//330/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r251": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org//350-30/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "420", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(d))", "Topic": "420", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-16", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-20", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-17", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-19", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-21", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(f)(3)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r330": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org//718/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(l)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "808", "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(i)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(iii)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(iv)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(i)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r396": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org//842-20/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r410": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "https://asc.fasb.org//855/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "912", "URI": "https://asc.fasb.org//1943274/2147482312/912-310-45-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "https://asc.fasb.org//1943274/2147483147/928-340-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(2))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(22))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(11))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(16))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-16(Column A))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-16(Column B))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-16(Column C))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-16(Column D))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-16(Column E))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-16(Column F))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-16(Column G))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-16(Column H))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-16(Column I))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-16(Column J))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-16(Column K))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(i)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(i)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "27", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(b)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(c)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(e)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(f)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(g)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(h)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-21", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(b)(2)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(a)(2)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(e)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(f)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(14))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(16)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(17))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(19))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(2)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(2)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(4))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(5)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(e))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(8))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(e))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-05(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-05(4))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Subparagraph": "(b)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "220", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(1)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(9))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(1)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(4)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 4))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column E)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column E)(Footnote 4))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Subparagraph": "(b)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Subparagraph": "(c)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Topic": "954", "URI": "https://asc.fasb.org//1943274/2147481058/954-310-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Topic": "954", "URI": "https://asc.fasb.org//1943274/2147481027/954-310-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)(1)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r571": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r572": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r573": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r574": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r575": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r576": { "Name": "Accounting Standards Codification", "Paragraph": "47", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482785/280-10-55-47", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r577": { "Name": "Accounting Standards Codification", "Paragraph": "12A", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r578": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "340", "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r579": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482548/350-20-55-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "182", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480401/815-10-55-182", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r580": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r581": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r582": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r583": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r584": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r585": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r586": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r587": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r588": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r589": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-20", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r590": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r591": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r592": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r593": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r594": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r595": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r596": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r597": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r598": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r599": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r600": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r601": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(b)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r602": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(a)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r603": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "55", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r604": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r605": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r606": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r607": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r608": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r609": { "Name": "Accounting Standards Codification", "Paragraph": "39", "Publisher": "FASB", "Section": "45", "SubTopic": "830", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480228/946-830-45-39", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r610": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "830", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r611": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "55", "SubTopic": "830", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r612": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "830", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r613": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r614": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r615": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r616": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r617": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r618": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r619": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r620": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r621": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-10", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r622": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-3", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r623": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "321", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r624": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r625": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r626": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r627": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r628": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r629": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(c))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r630": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r631": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r632": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r633": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r634": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r635": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r636": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r637": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r638": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r639": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(5))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r640": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r641": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r642": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r643": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r644": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r645": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r646": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r647": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org//310-10/tableOfContent", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r648": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r649": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r650": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r651": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r652": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org//450/tableOfContent", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r653": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r654": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r655": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r656": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r657": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r658": { "Name": "Accounting Standards Codification", "Paragraph": "27", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-27", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r659": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r660": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r661": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r662": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r663": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r664": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r665": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r666": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r667": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r668": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r669": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r670": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r671": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r672": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r673": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r674": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r675": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r676": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r677": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(5))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r678": { "Name": "Accounting Standards Codification", "Paragraph": "2B", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r679": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r68": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "https://asc.fasb.org//205/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r680": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r681": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(18))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r682": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(4)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r683": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r684": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r685": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r686": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r687": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r688": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column E)(Footnote 6)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1(e))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.3)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r93": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org//235/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.BB)", "Topic": "330", "URI": "https://asc.fasb.org//1943274/2147480581/330-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r98": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org//440/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r99": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "https://asc.fasb.org//470/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" } }, "version": "2.2" }